Impact of Acoustic and Tactile Multi-Modal Stimulation on Objective and Subjective Measures of Permanent Intractable Tinnitus: A Prospective Research Study by Hamilton, Caroline
  
 
 
IMPACT OF ACOUSTIC AND TACTILE MULTI-MODAL 
STIMULATION ON OBJECTIVE AND SUBJECTIVE MEASURES OF 
PERMANENT INTRACTABLE TINNITUS: 
  
A PROSPECTIVE RESEARCH STUDY 
 
Caroline Hamilton B.Sc. 
 
Masters Thesis 
Supervisor: Prof. Barak Pearlmutter 
Head of Department: Prof. Douglas Leith 
 
Hamilton Institute 
National University of Ireland, Maynooth 
Maynooth 
Co. Kildare 
June 2014 
  
  
  
  
 
 
 
 
 
       
Dedicated to my parents, my inspiration.  
 
 iii 
 
DECLARATION 
  
I hereby certify that this material which I now submit for assessment on the programme of study 
leading to the aware of Masters of Science is entirely my own work and has not been taken from 
the work of others save and to the extent that such work has been cited and acknowledged within 
the text of my work .  
 
This study was conducted through an independent collaboration between the National University 
of Ireland Maynooth, Hermitage Medical Centre and MuteButton Ltd.  
  
This study was funded by Enterprise Ireland and the Irish Research Council.  
  
  
  
Signed_______________________________________________   
ID No: 12251143          
  
  
  
  
  
  
   
  
  
  
  
  
iv 
 
ACKNOWLEDGEMENTS 
  
I’d like to express my deepest gratitude to Dr. Ross O’Neill for his constant support, 
encouragement and friendship over the course of this masters, without his expert advice and 
guidance, this work would not have been possible.  I’ve learnt a lot from Dr. O’Neill and it has 
been a thoroughly positive experience.  
  
I would also like to thank Prof. Barak Pearlmutter for providing me with such excellent direction 
and advice during my time in the Hamilton Institute.  Special thanks to all the people I’ve met 
during my time here, in particular Rosemary Hunt and Kate Moriarty for making everything run 
so smoothly (and for many good laughs!).  A special thanks to the Irish Research Council for the 
scholarship that allowed me to undertake this research. 
 
 Finally, I’d like to thank my husband Paul for his unwavering support and my two beautiful 
daughters Elly and Fia (for being such good sleepers).  Thank you for being so understanding of 
my study and for all the encouragement.  
  
  
  
   
  
  
  
  
  
  
  
  
  
  
  
v 
 
ABSTRACT 
  
Tinnitus is a complex condition comprising of three components, audiological, neurological and 
psychological which together produce the problems most commonly experienced by tinnitus 
suffers.  It is believed that brainstem structures, such as cochlear nuclei, play a major role in 
tinnitus generation and that perception occurs at the cortical level. Studies suggest that hearing-
loss causes a cascade of neuropathic effects in the central hearing system that is driven by 
maladaptive neuroplasticity.  This model is supported by Eggermont et al. (2006); Kaltenbach 
et al. (2005); Weisz et al. (2007) which report that tinnitus patients with an underlying hearing-
loss exhibited increased spontaneous firing rates, increased synchronicity and a reorganization 
of tonotopic maps in the auditory brainstem and auditory cortex.  Similarly, Parra & Pearlmutter 
(2007) reports that individuals with tinnitus were more susceptible to the Zwicker tone auditory 
illusion, suggesting that tinnitus may be related to a central phenomenon of frequency dependent 
adaptive gains in their hearing-response. 
 
Tinnitus may also partially involve the cranial somatosensory central nervous systems.  Shore et 
al. (2005); Herraiz et al. (2007) demonstrated a functional interaction between auditory 
brainstem structures and input from the branches of the trigeminal nerve and that stimulation of 
these nerves can qualitatively and quantitatively influence tinnitus perception.  Studies have 
shown that using Transcutaneous Electrical Nerve Stimulation (TENS) to stimulate the C2 
dermatome can have a significant beneficial effect on the perception of tinnitus (Vanneste et al., 
2010; Shore; 2005).    
  
We present the findings of a research study into the impact of acoustic and tactile multi-modal 
stimulation on objective and subjective measures of permanent intractable tinnitus.  This 16-
week study was conducted with 54 patients suffering from permanent intractable tinnitus.  
Patients demonstrated statistically significant mean improvements in Minimum Masking level 
(-8.6dB); Tinnitus Loudness Matching (-7.2dB); and Tinnitus Handicap Inventory (-9.4pts).  We 
discuss the implications of these findings for the clinical treatment of tinnitus and finally we 
make recommendations for the continued clinical investigation of this area of research.  
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CHAPTER ONE 
  
In this chapter, we give a brief overview of tinnitus and the underlying mechanisms involved.  
We introduce our Prospective Research Study using a novel Acoustic and Tactile Multi-modal 
Stimulation Tinnitus treatment.    
 
1.1 Introduction   
“Is my tinnitus going to get any worse?  The single most common question asked of me a 
Clinician specialising in Tinnitus”  
  
As a clinician specialising in tinnitus for over 10 years, I have been intrigued by the number of 
patients whom I meet every day with tinnitus, some extremely optimistic that their tinnitus may 
disappear whilst others live from day to day in fear of their tinnitus getting worse.  The vast 
majority have been told that ‘nothing can be done’.  As a Tinnitus Specialist, my career to date 
has been rewarding but also very challenging.  Sound therapy and counselling have been well 
defined and used routinely for treatment of tinnitus, but for the majority they have only given 
temporary relief.  Unfortunately to date, no therapy has been currently found to be uniformly 
effective in the long term treatment of tinnitus.  This motivated me to investigate how the current 
standard of care could be improved and help me to deliver better outcomes for my patients.   
  
This thesis looks at the prevalence, pathophysiology and mechanisms of tinnitus, the current 
standard of care, and efficacy, of treatments available. It also reports on a novel multi-modal 
stimulation treatment for tinnitus which uses proprietary multi-sensory stimuli to drive 
neuroplasticity in an attempt to alleviate tinnitus.  
  
Tinnitus is a common condition in which people experience a sound or noise which does not 
have a legitimate external source.  Eggermont & Roberts (2004) defines tinnitus as an auditory 
phantom sensation (ringing in the ears) experienced when no external sound is present.   
  
One in ten adults in Europe and in the USA has significant prolonged tinnitus, which is reported 
to have a severe effect on their quality of life as well as that of their families Hoffmann & Reid 
(2004).  Studies from different countries have indicated that the prevalence of tinnitus in adults 
falls in the range of 10-15% (Henry et al., 2005).  The Medical Research Council Institute of 
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Hearing Research (MRC IHR) carried out a robust and comprehensive study reported by Davis 
& El Rafaie (2000).  This was a longitudinal study which sampled a large population in four 
major cities in UK.  It revealed that 10.1% of adults experience tinnitus, 2.8% reported their 
tinnitus as moderately annoying, whilst 1.6% reported it as severe.    
  
To date there is no agreed medical definition of what constitutes tinnitus; this is probably a crucial 
reason as to why different studies typically show different incidence and prevalence values 
(Moller et al., 2010: 30).   Other studies have reported a wider range of outcomes, from 6% to 
30% tinnitus prevalence, which could be accounted for by the lack of general agreement of the 
definition and assessment of the condition (Sanchez, 2004; Quaranta et al., 1996).    
  
Tinnitus is known to occur as a concomitant of almost all the dysfunctions that involve the human 
auditory system (Naughton, 2004; Hoffman & Reid, 2004) but is most often associated with a 
sensory-neural or congenital hearing loss.  People with no obvious audiological, neurological or 
psychological disorders may also present with tinnitus.  Common risk factors include 
administration of certain medications, middle ear disease, and abnormalities in the vascular 
system, and ear surgery.  The most significant effects of tinnitus tend to be psychological. 
According to McKenna et al. (1991), 45% of patients with tinnitus were in need of psychological 
help and 86% of these subjects accepted it.   Such difficulties can include high levels of emotional 
stress such as depression, anxiety, irritability and anger; sleep difficulties; concentration 
problems; and disruptions to occupational, social, recreational, and interpersonal activities 
(Henry & Wilson, 2001).   
  
In many respects, tinnitus is likened to chronic pain, portraying similar features in terms of 
physiology, assessment and management (Moller, 1997; 2000). Both tinnitus and chronic pain 
appear to be mediated by neuropathic mechanisms and seem to involve central generation in 
more severe cases (Henry et al., 2005; Tonndorf, 1987; Moller, 2007). In a review of tinnitus 
from a neurophysiological perspective, Jastreboff considers the perceptual, emotional and 
reactive systems involved in tinnitus.  He claims that tinnitus does not always extend beyond the 
auditory system, and for these patients, tinnitus can be perceived only when the subject focuses 
on it.  Chronic and disabling tinnitus, on the other hand, occurs when patients fixate on their 
symptoms, and is related to inappropriate activation of the limbic system (Jastreboff, 1999; 
Hallam et al., 1988; Naughton, 2004), as shown in Fig 1.  
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Figure 1 Block diagram of the Neurophysiological Model of Tinnitus.  Image taken from Jastreboff (1999) 
 
Tinnitus is broadly categorised into ‘subjective’ and ‘objective’ tinnitus. Subjective tinnitus is 
described as a sound or noise that has no external source and is audible only by the patient. 
Objective tinnitus, although quite rare, is an audible noise that emanates from the ear and is often 
measurable audiologically. Studies have shown that subjective tinnitus is most often associated 
with a high-frequency (noise or age-related) hearing loss (Nicolas-Puel et al., 2002; Pickles, 
2008).  Tinnitus may present itself unilaterally, experienced in one ear only, or bilaterally, 
experienced in both ears, which is more common.   Unilateral tinnitus warrants further 
investigation as it is more likely to be a sign of an underlying pathology.   Some patients perceive 
the tinnitus sound centrally, finding it difficult to pinpoint the exact location.   Tinnitus is often 
qualitatively described as a single noise or tone, or as having two or more components.  The noise 
may also be continuous or pulsatile.  Although ‘tinnitus’ derives from the Latin word for 
‘ringing’, it can take a variety of qualitative forms including, buzzing, whistling, hissing, 
whooshing, or humming.  Some patients report experiencing tinnitus exclusively in quiet 
environments, whilst many others experience it even in noisy environments.  Many individuals 
report daily variability in the overall intrusiveness of the condition, whilst some individuals report 
a similar daily variance in the pitch and quality of their tinnitus.  Folmer et al. (2001) reports that 
chronic tinnitus is more persistent and can last for 6 months, in comparison to acute tinnitus 
which may last for days or weeks.  Davis & El Rafaie (2000) reports that it is important to 
distinguish between clinically significant and non-significant tinnitus.    
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Due to the subjective nature of this disorder and general lack of understanding of the underlying 
pathophysiology, treatment of tinnitus has been limited, controversial, and quite often 
unsuccessful.  Pharmacological treatment of tinnitus has proven ineffective, although some 
medications have been reported to relieve symptoms (Perry & Gantz 2000).  There are currently 
no pharmacological agents specifically recommended for the purpose of treating tinnitus (Dobie, 
1999). Non-pharmacological and surgical approaches have been used in certain cases with 
limited therapeutic effects.  Other treatments that have been proposed for tinnitus are: 
Antioxidant Therapy, Tinnitus Retraining Therapy (TRT), Repetitive Transcranial Magnetic 
Stimulation (rTMS), Transcranial Direct Current Stimulation (tDCS), Transcranial Alternating 
Current Stimulation (tACS) Sound Therapy, and Cognitive Behavioural Therapy (CBT) (Clinical 
Policy Bulletin, 2013; Henry et al., 2005; Vanneste & De Ridder, 2012; Baguley, 2002; AHRQ, 
2012).  
   
1.2 Acoustic Approach to Tinnitus Treatment: - Acoustic and Tactile Multi-modal 
Stimulation 
This thesis presents the findings of a research study into the impact of acoustic and tactile multi-
modal stimulation on ‘objective’ and ‘subjective’ measures of permanent intractable tinnitus.    
   
This intervention involves acoustic stimulation combined with tactile stimulation of the anterio-
dorsal surface of the tongue, using an intra-oral electrode array.  The study discusses the 
implications of these findings for the clinical treatment of tinnitus and makes recommendations 
for the continued clinical investigation of this area of research.  
  
The prospective study was conducted over a 16-week period with 54 patients (34 male, 20 female 
with a mean age of 47 years), suffering from permanent intractable tinnitus (>6 months) and with 
an accompanying high-frequency hearing-loss.     
  
Objective and subjective measures were used to measure and quantify the severity of tinnitus 
every two weeks for the duration of the study.  54 participants classified their tinnitus according 
to Visual Analogue Scale (VAS) and Tinnitus Handicap Inventory (THI).  The objective 
measures used to quantify their condition were; Tinnitus matching (TM), Tinnitus Loudness 
Matching (TLM) and Minimum Masking Levels (MML) (Vernon & Meikle, 2000).  Patients 
demonstrated statistically significant mean improvements in Minimum Masking level (-8.6dB); 
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Tinnitus Loudness Matching (7.2dB); and Tinnitus Handicap Inventory (-9.4pts).  We discuss 
the implications of these findings for the clinical treatment of tinnitus and finally we make 
recommendations for the continued clinical investigation of this area of research.  
  
1.3 Overview   
In Chapter Two, we provide a general overview of the complex condition of tinnitus, its 
prevalence, pathophysiology and overall impact.  We discuss the audiological, neurological and 
psychological components of tinnitus, which together produce the problems most commonly 
experienced by tinnitus sufferers.  We also discuss the pharmacological and non-pharmacological 
treatments that are currently available.   Chapter Three, briefly reviews the relevant parts of the 
Peripheral and Central Nervous systems that are relevant to our study. This includes the 
Peripheral and Central Auditory systems, somatosensory system and the cranial nerves. Chapter 
Four gives a brief overview of the auditory system and the mechanoelectrical transduction of 
sound pressure into neural action potentials.   
 
We pay particular attention to the human sense of hearing, the relationship between tinnitus and 
high frequency hearing loss and neural pathologies in the central nervous system which drive 
neuroplasticity. Chapter Five discusses the anatomical and functional links between the auditory 
and somatosensory systems.  We explore these cortical and subcortical links, how they influence 
the perception of sound, and their implications for the treatment of tinnitus.  We propose two 
novel hypothetical treatments that utilise auditory-somatosensory interactions and outline our 
motivation for selecting and experimentally determining the clinical efficacy of one of these two 
treatments.  Chapter Six provides the general methods of the clinical trial, including sample size 
and recruitment, eligibility criteria, trial procedures, outcome measures, data collection and 
analysis.  Chapter Seven reports on the impact of acoustic and tactile multi-modal stimulation 
treatment for tinnitus.  The results reported verify the clinical benefit and user tolerability of the 
treatment.  Chapter Eight, the final chapter, highlights and examines the main findings of this 
research, discusses them in the broader clinical context and finally processes recommendations 
for further investigations.  
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CHAPTER TWO: OVERVIEW OF TINNITUS 
  
In this chapter, we provide a general overview of the complex condition of tinnitus, its 
prevalence, pathophysiology, and overall impact.  We make reference to the audiological, 
neurological, and psychological components of tinnitus, which together produce the problems 
most commonly experienced by tinnitus sufferers.  We also discuss the pharmacological and non-
pharmacological treatments that are currently available.     
  
2.1 Tinnitus  
Tinnitus is the perception of sound in the absence of external auditory stimulation.  In both 
clinical and academic contexts, patients are described as presenting with symptoms of either 
‘objective’ or ‘subjective’ tinnitus.  As objective tinnitus is quite rare, some believe that all 
tinnitus should be defined as subjective and classified instead by origin, either as 
neurophysiologic or somatic tinnitus (Henry, 2011; AHRQ, 2012). In keeping with the prevalent 
practice this study will focus on subjective or neurophysiologic tinnitus which will be referred to 
simply as ‘tinnitus’.   
  
2.2 Prevalence   
Numerous studies into the prevalence of tinnitus indicate that the condition is becoming an 
increasingly significant health problem.  It is widely believed that the majority of people have 
some level of tinnitus however, given the lack of an accepted classification of the condition; 
accurately quantifying its prevalence is difficult (Heller, 2003).   The largest longitudinal study 
was carried out by the Medical Research Council Institute of Hearing Research (Davis & Rafaie, 
2000). The study interviewed 48,313 people, 10.1% reported that their tinnitus is spontaneous, 
lasting for 5 or more minutes at a time and 5% described their tinnitus as moderately annoying 
or severely annoying.  0.5% reported that their tinnitus had a severe effect on their quality of life.  
These figures are consistent with data collected by the American Tinnitus Association (ATA) 
which reports that tinnitus may be experienced by approximately 50 million Americans (ATA 
2004).  Hoffman & Reed (2004) made reference to six large studies in different countries and 
reported prevalence of prolonged tinnitus, varying between 4.4% and 15.1% for adults.  
Comparable prevalence rates have been reported in several studies from the UK, Sweden, 
Norway and the US.  Moller et al (2010: 29-34) reported the prevalence of tinnitus in these studies 
were not the same for the different age groups however the majority of studies agreed that the 
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risk of developing tinnitus increases with age up to about 65 to 70 years, after which it becomes 
constant or decreases slightly (Moller et al., 2010: 29-34; Henry et al., 2005; Davis & El Rafaie, 
2000: 1-24).   
   
The association between presbyacusis and tinnitus contributes to the misconception that tinnitus 
is exclusively a complaint of the elderly.  However, many people develop tinnitus in their middle 
age and younger (Naughton, 2004).  Baguley (2002) reported that women are also more likely to 
report tinnitus than men and occupational noise and lower socio-economic class are also 
associated with increased tinnitus, however further studies are required to determine these 
factors.      
  
Meikle (2003) reviewed the prevalence of tinnitus, and reports that it is much higher than the 
number of patients who seek treatment (Davis, 1995, Hinchcliffe, 1961; Leske, 1981), thus 
indicating that many individuals who experience tinnitus do not find it to be a significant or 
debilitating problem.   Nearly 50 million Americans experience tinnitus with 10-12 million 
seeking medical attention due to chronic symptoms.   According to the American Tinnitus 
Association (ATA) 1-2 million American tinnitus sufferers are debilitated by their condition 
where their cognitive abilities are compromised and quality of life seriously impacted.  This year, 
840,000 Veterans were in receipt of disability compensation, costing $1.28 billion annually, 
which the Department of Veterans Affairs (VA) expects will increase to $2.75 billion by 2016 
(ATA, 2013).  The Royal National Institute for the Deaf (RNID) estimates that there were 12.6 
million chronic tinnitus suffers worldwide in 2007 and predicted that this would grow to 22.3 
million by 2015 (RNID, 2005).  
  
2.3 Pathophysiology of Tinnitus  
According to McKenna et al., (2011) tinnitus is an extremely common symptom affecting 
‘humanity’.  The greatest challenge is determining a clear definition and classification of tinnitus 
due to its multiple aetiologies and highly subjective presentation of its symptoms.  It can range 
from an intermittent tinnitus perception to a constant intrusive tinnitus; it may present itself 
unilaterally or bilaterally, or may be perceived in the head.   Tinnitus may be linked to a range of 
physiological conditions or psychological experiences particularly if the onset is sudden.  
However the exact mechanism is still not fully understood. For some individuals, the loudness, 
pitch and quality of the tinnitus can vary from day to day.    
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As a symptom, tinnitus may be associated with a number of audiological conditions including 
impacted wax, adverse reactions to ototoxic medications, or acoustic tumours.   It is most 
commonly associated with sensory-neural hearing loss; in particular, noise induced or age related 
hearing loss (Coles, 2000; Davis & El Rafaie et al., 2000; Saunders, 2007).   It may also be 
associated with symptoms such as hyperacusis (Andersson et al., 2001; Dauman & Bouscau-
Faure, 2005).  As noted, tinnitus is most commonly associated with hearing loss.  According to 
the Tinnitus Archive of the Oregon Health and Science University the most common cause of 
tinnitus is noise exposure (approx. 24%) followed by head and neck injuries (approx18%) 
(Eggermont, 2006). The causal relationship between hearing loss and tinnitus will be discussed 
in further detail.  However, tinnitus has also been reported in individuals with normal hearing 
within the recommended audiological range of 250 to 8 kHz (Barnea et al., 1990).  However 
Salvi et al. (2009) state that when testing is carried out above 8 kHz, cases of individuals with 
tinnitus without hearing loss are quite rare.  Several tinnitus classifications have been proposed 
(McCoombe, 2001; Dauman, 1992; Davis & El Rafaie, 2000).  Davis & Rafaie (2000) reports 
that it is important to distinguish between clinically significant and non-significant tinnitus.  
Dauman (1992) makes a distinction between ‘normal’ (lasting less than five minutes, occurring 
less than once a week and experienced by most people) and ‘pathological’ tinnitus (lasting more 
than five minutes, occurring more than once a week and usually experienced by people with 
hearing loss.    
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Figure 2 TRI Flowchart for Patient Management.  Image taken from TRI Tinnitus Clinic Network, Biesinger et al. (2010) 
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2.4 Mechanisms   
Numerous pathophysiological mechanisms and models have been proposed as contributors to 
tinnitus (Baguley, 2002; Eggermont & Roberts, 2004; Kaltenbach et al., 2005; Weisz et al. 2007).  
Tyler et al., (2008); Landgrebe (2010) report that efforts towards establishing tinnitus subgroups 
are currently underway.  Based on these subgroups the Tinnitus Research Initiative (TRI) is 
already recommending different patient pathways for these subgroups that encompasses 
treatment and management strategies as shown in Fig 2.  
  
Cochlear damage is believed to be the initiating factor which leads to altered patterns of neural 
activity along the central auditory pathway (Bauer et al., 2008).   Some suggest that after cochlear 
damage a cascade of changes occurs in central auditory pathways, and some of these may serve 
as ‘neural codes’ for tinnitus (Eggermont & Roberts, 2004). Recent studies have demonstrated 
enhanced spontaneous firing rates (SFRs) in central acoustic pathways (Kaltenbach et al., 2005), 
tonotopic reorganisation, and altered synchronous cortical activity (Seki and Eggermont, 2003; 
Weisz et al., 2007).    
  
2.5 Limbic System   
Reviews of tinnitus from a neurophysiological perspective (Jastreboff, 1990; Jastreboff, 2004) 
consider the perceptual, emotional and reactive systems involved.  It is claimed that for many 
patients neurological involvement does not extend beyond the auditory system, and for these 
patients, tinnitus can be perceived only when the subject focuses on it.  Chronic and disabling 
tinnitus, on the other hand, occurs when patients fixate on their symptoms and thus cause 
inappropriate activation of the limbic system (Naughton, 2004; Hallam et al., 1988). The 
lemniscal pathways use the ventral part of the medial geniculate body, the neurons of which 
project to the primary auditory cortex, whereas the extralemniscal pathways otherwise known as 
the non-classical pathways use the dorsal part of the medial geniculate body that projects to the 
secondary auditory cortex and association cortices, thus bypassing the primary cortex. The non-
classical pathways can be modulated by somatosensory input and studies have shown evidence 
of extralemniscal cross-modal interaction in both children and adults with tinnitus. Moller & 
Rollins (2002); Moller et al. (1992); Lockwood et al. (1998) demonstrated that the limbic 
structures which support the involvement of the extralemniscal auditory system are more active 
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in response to sound stimulation in some patients with tinnitus.  The limbic system mediates the 
emotional and sympathetic nervous system activity which drives maladaptive neuoroplasticity 
which may be a contributing factor to tinnitus (Saunders, 2007; Kaltenbach et al., 2005).  
Activation of the limbic system produces changes in mood, arousal and thoughts which may be 
associated with major depression, anxiety, and other psychosomatic and or psychological 
problems that lead to progressive deterioration of quality of life (Sullivan, 1993; Lockwood, 
1998; Langguth et al., 2011).   
  
 
Figure 3 Vicious Cycle of Tinnitus.  Image taken from Holt Hearing & Balance (2013) 
  
2.6 Impact   
The initial onset of tinnitus is quite often associated with stress, which can lead to negative 
thoughts and emotions, particularly if the tinnitus persists (Schmidtt et al., 2000). Tinnitus also 
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becomes a problem when it is perceived as a threat, appears continuously intrusive, or when 
patients have difficulty coping (Hazell, 1998).  Tinnitus can lead to a repeating cycle of 
annoyance, mood changes, fear, and anxiety, all of which are associated with tinnitus severity 
(Henry et al., 2005), as displayed in Fig 3 above.  
  
The effects of Tinnitus include both medical and psychological components.  Regardless as to 
the underlying diagnosis it is believed that the brain generates the ‘illusory sound’, and 
psychological factors begin to emerge that determine how the person copes with their tinnitus.  
Distress caused by the initial onset or continued intrusiveness of tinnitus may negatively 
exacerbate underlying physical or psychological issues. Physical effects include disruption of 
daily activities, disturbance of sleep, or new side effects to their long term medications.   
  
Hallam (1988) reports difficult in hearing, emotional stress and sleep as the three most commonly 
made complaints about tinnitus.  Sanchez & Stephens (1997) concluded that the single most 
common problem in everyday life for tinnitus patients was sleep disturbance, with 71% reporting 
it as their main issues. Davis et al. (1995) reported 5% of individuals in a normal population have 
sleep disorders with tinnitus as the casual factor.  Patients’ anecdotally reported that tinnitus 
wakens them from their sleep, but Folmer and Griest (2000) and Axelsson (1989) report that this 
may not be the case as patients with insomnia often appear to experience more severe tinnitus in 
comparison to patients who do not have problems sleeping.  
  
Psychological effects include learned helplessness, anxiety depression, decline in memory and 
concentration and emotional self-neglect.  Several studies have discussed similarities between 
the patient profiles and therapeutic approaches for chronic pain and tinnitus sufferers (Moller, 
2000; Tonndorf 1987).  McKenna et al. (2011) state that although individuals with intrusive 
tinnitus perceive a sound, it often behaves more like pain especially in terms of the variety of 
reactions.  The brain continues to develop perceptual experiences even after the loss of function 
of peripheral sensory cells (Rauschecker, 1999).  Both disorders are subjective, intractable, and 
distressing, which can have a major impact on the quality of life of the sufferers (Kirsch et al., 
1989; Meikle et al., 1995).   
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Sullivan et al. (1988) studied the association between disabling tinnitus and affective disorders.  
The results demonstrated that tinnitus sufferers presented a greater lifetime prevalence of major 
depression than a control group of subjects with hearing loss and no tinnitus. The authors 
concluded that the results were in accordance with the hypothesis that disability is strongly 
associated with depression.  Scott & Lindberg (2000) also confirmed the link between anxiety, 
depression, stress, and chronic tinnitus.   
  
It has been reported that tinnitus loudness rarely correlates with distress.   Hallum et al. (1988) 
suggested that perception of and reaction to tinnitus is not one and the same. A study by 
Erlandsson et al. (1992) suggested that the patients’ perception of the condition and their 
management of it can predict the level of impact.  This supports Jastreboff’s theory (1990) that 
tinnitus is perceived only when the individual focuses and reacts to it.  Conversely Willebrand et 
al. (2001) suggest that failing to acknowledge the condition can increase the associated distress.   
  
As only a small proportion of people who experience tinnitus are affected by it, it is important to 
make a distinction between awareness of and distress caused by tinnitus (McKenna et al., 2010).   
  
2.7 Measurement  
It is widely acknowledged that there are a lack of objective tools to measures and quantify 
tinnitus.   As a condition, tinnitus is highly subjective and influenced by a range of complex 
factors including cultural and social.  Tinnitus is a complex and multidimensional condition 
which can impact physical, psychological and social aspects of a patient’s life.  Various measures 
can be used to determine the presence and severity of tinnitus (McCoombe et al., 2001).  A 
thorough clinical examination, including a complete patient history, audiological assessment and 
in some cases further investigation, is paramount in determining potential causes.   
 
The assessments of tinnitus severity and its impact also depend on valid and reliable self-report 
instruments. Self-report measures are increasingly used in tinnitus research and in the 
management of tinnitus patients.   The use of robust outcome measures is of great importance.  
There are a number of validated questionnaires and inventories for the assessment of tinnitus 
impact (Andersson et al., 2007: 92).  Psychological grading scales can also aid in the 
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discrimination between clinically significant and non-significant tinnitus (Erlandsson, 2000). The 
Tinnitus Functional Index (TFI) is a new self-report questionnaire that has documented validity 
both for scaling the severity and negative impact of tinnitus and for measuring treatment-related 
changes in tinnitus (Meikle et al., 2012).  
 
2.7.1 Subjective Measurements:   
Visual Analogue Scale (VAS)  
The VAS is a well-known psychometric measure of subjective attitudes and is used frequently in 
pain management (Wewers and Lowe, 1990) and also recommended for use in tinnitus research 
(Axelsson et al., 1993).  The VAS provides consistent and reliable results and is used to evaluate 
the self-perceived loudness pitch and severity of tinnitus on a rating scale of 1 to 10, with 1 being 
'barely audible' and 10 being 'intolerable (Miekle, 2008).  The VAS has been validated for use in 
a number of tinnitus studies (Axelsson et al., 1993). Adamchic et al. (2012) reported that VAS 
annoyance and VAS loudness are valid and effective measurements and provide good test-retest 
reliability.       
 
Tinnitus Hearing Inventory (THI)  
THI measures are used to assess the impact of tinnitus on the participant and reports have 
confirmed its test-retest reliability (Newman et al., 1998) and a high convergence with other 
questionnaires (Baguley et al., 2000).  This is a 25-item self-administered questionnaire for the 
measurement of tinnitus handicap and the impact of tinnitus on everyday functioning (total score 
ranging from 0 to 100, with a higher score indicating greater handicap).    Based on the 
(confidence intervals) CI estimates, it is suggested that treatment is effective if a change of 20 
points is noted pre-post treatment (Newman et al., 1998).    
 
THI is valuable in assessing tinnitus severity, however it is limited in that it is not designed or 
validated to measure effectiveness of tinnitus interventions (Kamalski et al., 2010).  Meikle et al. 
(2008) acknowledges the THI to be both valid and reliable in measuring self-reported tinnitus 
handicap.  Although verified, it does have areas of weakness.  There are a wide variety of 
questions regarding sleep, stress, etc., but as a measure the THI doesn’t separate out these 
confounding factors.  Henry et al. (2005) recommend open ended questionnaires which could 
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help improve this, however Schwartz (1999) reports that open ended questionnaires present with 
a number of discrepancies.  
 
2.7.2 Objective Measurements  
Psychoacoustic assessment, including Tinnitus Matching (TM), Tinnitus Loudness Matching 
(TLM), and Minimum Masking Levels (MML), are determined by establishing the frequency, 
intensity, and minimum masking level of the patient’s tinnitus. These measurements are 
expressed in Hertz (Hz) and Decibels (dB), respectively (Henry & Meikle 2000). Another 
assessment is Residual Inhibition (RI), which measures the temporal duration of tinnitus 
suppression immediately following a period of masking.   
   
2.8 Management   
Currently both pharmacologic and non-pharmacologic treatments as described below are used 
for managing tinnitus. These range from different forms of Sound Therapy; Tinnitus Retraining 
Therapy, Cognitive Behavioural Therapy, Neuro-feedback, and various forms of Electrical 
Stimulation.  These therapies tend to provide symptomatic relief, but tend not to be overly 
effective in eliminating tinnitus.  The chosen treatment modality is often a function of the severity 
of the condition.  There are a diverse range of available treatments, the benefit and limitations of 
which have been discussed in numerous articles Langguth et al (2011). However many of the 
studies have come under criticism as they were not considered well-controlled trials and lacked 
a common outcome measure (Dobie, 2004; Henry, et al., 2005). As tinnitus has a vast range of 
aetiologies (Hoffman & Reid, 2004) patients tend to be grouped mainly by the severity of their 
tinnitus, based on one of many questionnaires (Newman & Sandridge, 2004; Eggermont et al 
2011).     
 
Vanneste & De Ridder (2012) report that many studies only evaluate transient changes in tinnitus 
perception without the analysis of long-term effects, and other studies only report on 
improvement of tinnitus distress, without verifying the improvement in tinnitus intensity, and 
some studies report statistically significant improvements with low effect sizes revealing only 
‘marginal clinical relevance’.  Dobie (1999) further suggests that by adopting an agreed outcome 
measure the range of therapeutic approaches could be compared more effectively.   
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2.9 Pharmacotherapy Treatment Approaches  
Studies refer to a range of pharmacological treatments which have been proposed to relieve 
tinnitus, albeit with limited success (Perry & Gantz, 2000; Patterson & Balough, 2006; Nobel, 
2008; Henry et al., 2005; Langguth, 2009).   Pharmacological agents specifically administered 
for the treatment of tinnitus include; antidepressants, vasodilators, intravenous lidocaine, 
barbiturates, antihistamines, beta histamine, and benzodiazepines.  However, Dobie (1999) 
states that the use of drugs should only be considered in the treatment of symptoms which can 
co-exist with the tinnitus, i.e., sleep deprivation, depression, and anxiety. Sziklail et al. (2011) 
referred to a recent study of the drug Pramipexole a dopaminergic agent which is a newer 
medication that has been reported to be an effective agent against tinnitus with presbyacusis and 
is currently being further investigated (Henry et al., 2005).   Langguth et al. (2009) stressed that 
a drug that produced only a small but significant effect would have an enormous therapeutic 
impact and urged for more effective pharmacotherapies for this huge and growing market 
(Vanneste & De Ridder, 2012).   
  
Fornaro & Martino (2010) reported that for some individuals the use of alternative medications 
have reduced the severity of tinnitus.  These treatments include ginkgo biloba, zinc, melatonin, 
lidocaine, magnesium, botulinum toxins, and B vitamins, but as discussed below much of the 
evidence is anecdotal (Pandey, 2011).  
  
2.10 Non- Pharmacotherapy Treatment Approaches  
2.10.1 Cochlear Implants  
Cochlear implants have been reported to suppress tinnitus in nearly 50-80% of patients (House, 
1976; Berliner et al., 1987; Henry et al., 2005).  Cochlear implants were found to be effective for 
reducing tinnitus (Vernon, 2000; Ruckenstein & Tyler, 2004) an effect which may arise from 
masking by the newly perceived sound or from electrical stimulation of the auditory nerve 
(Dauman, 2000).  Cochlear implants are a viable treatment option for individuals who are 
profoundly deaf with severe intractable tinnitus (Henry et al., 2005).  The reorganising of the 
central auditory nervous system after restoration of peripheral sensory input may help in reducing 
tinnitus (Moller, 2003; Del Bo & Ambrosetti, 2007).  Although it has been reported that cochlear 
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implants exacerbate tinnitus (Tyler, 1995), an interesting fact is that unilateral cochlear 
implantation has been associated with reduction in contralateral tinnitus in up to 67% of 
individuals (Andersson et al., 2007: 130).    
 
2.10.2 Complementary Therapies  
Complementary therapies over the years have been recommended for relieving tinnitus, but few 
studies have been published regarding their efficacy.  Therapies range from herbalism, 
homeopathy, aromatherapy, massage, osteopathy (include cranial sacral therapy), acupuncture, 
biofeedback, hypnosis, magnets, oxygen yoga, prayer, and meditation.  Acupuncture is widely 
used to treat tinnitus (Zhang, 2002) and controlled trials carried out recently report it be an 
effective treatment (Tan, 2007) however Park (2000) carried out a systematic review of 
acupuncture and concluded that there was insufficient randomised control trial (RCT) evidence 
to demonstrate its effectiveness.  Although many therapeutic effects are attributed to Ginkgo 
biloba (Morgenstern, 1997), there is very little evidence to support this (Hilton, 2004).   Due to 
its subjective nature, tinnitus may be particularly amenable to placebo-based therapies.   
 
2.10.3 Temporomandibular Joint Dysfunction (TMJ)  
TMJ disorder is a very common disorder which arises from the temporomandibular joints and 
associated structures. It is also known as temporomandibular pain dysfunction or craniofacial 
disorder.  Symptoms of TMJ include pain, tenderness, abnormal bite, headaches and facial 
sensitivity.  Tinnitus can also be a symptom of temporomandibular joint dysfunction.   In most 
cases, changing to a soft diet, jaw muscle exercises or use of anti-inflammatory or analgesic 
drugs can help.  For those that grind their teeth, dental treatment or bite realignment can help 
relieve the symptoms of TMJ pain and associated tinnitus for some individuals (Morgan, 1996).  
This can be disposed of when normal functional is restored.  Anderson et al. (2007) made 
reference to studies by Erlandsson et al. (1991); Wright & Bifano (1997) who have shown that 
treatment of TMJ improves associated tinnitus.   
 
2.10.4 Laser therapy   
Laser powered or soft lasers have been suggested as a potential treatment for tinnitus.   They are 
believed to stimulate the mitochondria in the cells of the ear to produce energy through the 
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production of ATP (adenosine triphosphate) and in return repairs the damaged tissue.  Laser 
therapy can offer significant benefit in treatment of tinnitus, but further experimental studies are 
needed to assess the efficacy (Gungor et al., 2008). In addition to different pathophysiological 
mechanisms of inner ear disease and diverse theories on the nature of tinnitus, the methodical 
differences in study design, treatment schedules, and irradiation parameters could cause a wide 
range of outcomes (Tauber et al., 2003).  Nakashima et al. (2002) and Teggi et al. (2009) 
concluded that Transmeatal laser irradiation was ineffective for treatment of tinnitus.    
 
2.10.5 Transcranial magnetic stimulation  
Transcranial Magnetic Stimulation (TMS) and Repetitive Transcranial Magnetic Stimulation 
(rTMS) are techniques that scientists are now refining for tinnitus patients.  Depending on the 
stimulation frequency, this magnetic field can either decrease or increase the electrical 
excitability of the brain.  A number of studies have shown that TMS may be effective in the 
treatment of tinnitus (Khedr et al., 2008; Kleinjung et al., 2005; Pridmore et al., 2006; Smith et 
al., 2007).  However Meng et al. (2011) in Cochrane Review evaluated the effectiveness of rTMS 
versus placebo in patients with tinnitus and reported that it is a safe treatment for tinnitus in the 
short term, however there was insufficient evidence regarding long term treatment.  They 
concluded that more prospective, randomised placebo controlled double blind studies with larger 
samples are needed with uniform, validated tinnitus specific questionnaires as well as 
measurement scales (Clinical Policy Bulletin, 2013).  
 
2.10.6 Educational Therapy  
For a lot of people with tinnitus, reassurance and explanation is all that is required. Simply 
understanding what is causing the problem is a great help in hastening the problem.  This is 
because when tinnitus begins, it is common to feel anxious and fearful, but then it usually settles 
down as the brain gradually “habituates” to this new sensation and through its central auditory 
system gradually learns to ignore it (McKenna et al., 2011).    
2.10.7 Relaxation Therapy  
Relaxation therapies such as biofeedback aim to manage stress by changing the body’s reaction 
to it by teaching individuals to manage their automatic body functions such as muscle tension 
and body temperature.  Therapists offer strategies to divert the individual attention away from 
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their tinnitus-related symptoms.  Although this may not eliminate tinnitus, the main aim is to 
improve an individual’s quality of life (Ireland, 1985) by providing them with behavioural and 
relaxation techniques.  
 
2.10.8 Tinnitus Retraining Therapy (TRT)  
Tinnitus Retraining Therapy (TRT) which was developed by PJ Jastreboff in the 1990’s, is a 
commonly used habituation programme which combines sound therapy with directive 
counselling.  Sound is used to make the tinnitus less noticeable as opposed to masking it out, and 
it is used in conjunction with an intense form of direct counselling based on the Jasstebroff’s 
‘neurophysiological model’ (McKenna et al., 2010).  The combination of sound therapy and 
counselling with TRT is designed to lead to habituation, which means that the tinnitus-related 
neuronal activity is blocked from reaching the limbic and autonomic nervous system and 
consequently there are no negative reactions to the tinnitus (Jastreboff & Hazell, 2006).  The long 
term impact of TRT is limited (Dobie, 1999) and it can take 1-2 years to observe stable effects.  
It has been noted that there is need for better experimental designs in the studies of TRT efficacy 
(Wilson et al., 1998; Kroner-Herwit et al., 2000; Henry et al., 2005).   
  
2.10.9 Neuromonics Treatment  
Neuromonics combines the use of broadband noise and relaxing music with a structured 
programme of counselling and support by clinicians specially trained in tinnitus rehabilitation.  
It claims 90% success rates for patients who persist with the treatment and a 40% reduction in 
tinnitus intensity.  Davis et al. (2007) (2008) found that the treatment provided rapid and profound 
improvements to the severity of tinnitus symptoms and their effect on the individual quality of 
life. The difference between the two groups was statistically significant. Goddard et al. (2009) 
confirmed that Neuromonics appears to be useful as a means of significantly reducing the effects 
of tinnitus on an individual’s daily life, but future studies are needed to look at larger groups of 
subjects and longer follow-up regarding the efficacy of this device.  
2.10.10 Cognitive Behavioural Therapy (CBT)  
Tinnitus is associated with many psychological problems as previously discussed (Langguth et 
al., 2011).  An intervention like Cognitive Behavioural Therapy (CBT) by itself does not 
influence the subjective loudness of tinnitus or improve the associated depression, but it may 
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effectively increase an individual’s quality of life by increasing the patient’s ability to deal with 
chronic tinnitus (Martinez-Devesa et al., 2010). The goal of CBT in tinnitus treatment is to 
recognise and then correct any negative thoughts and emotions an individual has about their 
tinnitus, (Henry & Wilson, 2001).    Studies have demonstrated that CBT has helped patients 
reduce tinnitus related distress Zachriat & Kroner-Hewrig (2004) and a Cochrane Review has 
also demonstrated CBT can have an overall effect on the qualitative aspects of tinnitus and also 
improve how the patients manage the condition (Martinez-Devesa et al., 2007).    
 
2.10.11 Transcutaneous Electrical Stimulation (TENS)  
Transcutaneous Electrical Stimulation (TENS) machines are commercially available devices 
which apply pulsed electrical stimuli to provide pain relief.  Siedman & Jacobson (1996), in a 
review of tinnitus, indicated Electrical Stimulation (ES) as a possible treatment modality for 
patients with severe tinnitus.   ES for suppression of tinnitus has been researched for many years 
and it has been indicated as a promising area of investigation (Dauman, 2000; Rubinstein & 
Tyler, 2004).  The exact mechanism by which ES suppresses tinnitus is still unclear and the 
effects reported have varied considerably (Moller, 2010: 727).   Shulman (1987) were one of the 
first to describe the results from cutaneous ES around the ear.  Various types of ES have been 
used, such as high frequency electrical current, direct current (DC), and pulse trains at different 
rates (Moller, 2011: 727).  
  
Commercial electrical stimulation tinnitus suppression devices were developed, but are no longer 
available (Henry et al., 2005). A number of studies were conducted with a tinnitus suppression 
device, the Audimax Theraband (Audimax Corp), which was developed during the 1980’s.  This 
wearable device used a headband to hold electrodes which deliver low level alternative current 
(AC) against each mastoid.  The best controlled study of the theraband showed some limited 
therapeutic benefit Dobie et al. (1986), but the device is no longer being produced.  Henry et al. 
(2005) also made reference to other electrical stimulation studies which reported some limited 
effectiveness, although he reports that placebo effects could have influenced the results (Dauman, 
2000).  
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The use of ES has demonstrated some positive findings and the general consensus is that the DC 
is the most effective type of current, but causes tissue damage (Dobie et al., 1986; Hazell et al., 
1989; Staller, 1998). AC does not cause tissue damage, but is only effective for a limited number 
of patients.  ES is therefore still considered an experimental treatment and has not been 
demonstrated to be useful for common clinical practice (Henry et al., 2005).  For the purpose of 
this study, we shall discuss ES of the trigeminal nerve in further detail in Chapter Five.   
 
2.10.12 Sound Therapy   
Various treatment strategies for tinnitus use sound therapy in the form of wearable devices such 
as hearing aids and maskers and non-wearable devices such as table top sound generators or 
maskers (Schechter & Henry, 2002; Henry et al, 2005).  When used over long periods, noise 
generators which are set to masking sound levels can produce an overall reduction in tinnitus 
symptoms.  Roberts (2010) reports that sound therapy has little effect once the external stimulus 
is discontinued with ‘residual inhibition’ (temporary relief when stimulus is turned off) lasting 
for approximately 2 minutes, resulting in short-term habituation effects. If the noise generator is 
set to produce sound levels below the masking level, the patient is conscious of both the noise 
from the masker and their tinnitus, which tends to result in greater improvements, particularly if 
the device is continually used for over a year. Typically between 60 and 70% of patients receiving 
this type of treatment will experience a useful reduction in their tinnitus symptoms (Baracca, 
2007; Newman, 2012).  
 
Hearing Aids have long been recognised to reduce the bothersome effects of tinnitus (Saltzman 
& Ersner, 1947; Surr et al., 1985; Melin et al., 1987; Newman, 1996; Henry et al., 2006).  
Masking devices in combination with amplification have been recommended for about 60% of 
patients treated in a major tinnitus clinic (Vernon & Miekle, 2000) and hearing aids alone are 
sometimes sufficient to provide masking relief (Del & Ambrosetti (2007); Trotter & Donaldson 
(2008).   Vanettse & De Ridder (2012)  make reference to hearing aids having only a marginal 
effect on the intensity of tinnitus and referred to studies where the perception of tinnitus was 
affected only weakly in a conventional amplification group and not at all affected in a high-
bandwidth amplification regime (Moffat et al., 2009).   
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The efficacy of tinnitus masking is difficult to assess from the current literature, as the majority 
of studies only report the outcomes of treatment for those who purchased and used the devices, 
there are no reports on those who are not referred for treatment, who don’t actually purchase 
devices, who purchase devices but don’t use them, or those patients who return their devices  for 
various reasons (Henry et al., 2005), and only a few authors include placebo control studies 
(Hobson et al., 2010).  
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CHAPTER THREE: NERVOUS SYSTEM 
  
In this chapter, we briefly review the relevant parts of the Peripheral and Central Nervous systems 
that are relevant to our study. This includes the Peripheral and Central Auditory systems, 
somatosensory system and the cranial nerves.   
  
 
Figure 4 The Neuron: Chemical Synapse.  Image from Wikipedia Commons (2013) 
 
3.1 Neurons  
Neurons contain nerve processes called dendrites and axons and a cell body called the soma 
which, transmit signals between different parts of the body, as shown in Fig 4. They release 
chemicals known as neurotransmitters at junctions called synapses, which give a command to the 
cell and the entire communication process typically takes only a fraction of a millisecond.  
  
Neurons create electric impulses known as action potentials (spikes hereafter) which play a 
central role in cell to cell communication.  A neuron that emits an action potential is often said 
to ‘fire’. The spike occurs in response to an electrical charge inside the cell membrane.  This 
change is due to channels opening in the dendrites in response to electrical (voltage gated 
channels), chemical (ligand gated channels) or mechanical (mechanical gated channels) stimuli, 
allowing mobile charges to enter the cell.    
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 The generation of spikes is controlled by a region of the neuron called the trigger zone.  These 
spikes travel right through the long distance an axon can span to the target cells.  When action 
potentials arrive at the synapse (junction between two neurons) it triggers a complex chain of 
biochemical processing steps that lead to a release of neurotransmitters from the presynaptic 
terminal into the post synaptic cleft.  Some neurons emit action potentials constantly, at rates of 
10-100 meters per second.  Some neurons are quiet but occasionally emit a burst of spikes 
(Barnes, 2007).   The sensory areas receive information (nervous impulses) from all body parts 
and the association areas analyse the impulses and make decisions.  Sensory neurons capture 
information about their environment and express it in terms of language of the nervous system.   
  
In engineering terms, the human senses are essentially a set of analogue to digital converters.  
They convert the analogue signals of the world such as light and sound, into the digital signals 
of the nervous system, the spikes.  This process is known as sensory transduction. The motor 
areas send impulses (orders) to muscles or glands.  These impulses are carried by 43 pairs of 
cranial nerves, 31 pairs of nerves are in the spinal cord and 12 are in the brain stem.  Due to the 
nature of this study, the trigeminal nerve and vestibular cochlear nerve will be discussed in more 
detail later in this chapter.     
  
3.2 Central Nervous System (CNS)  
The Central Nervous System (CNS) which is the most complex part of the Nervous System (NS) 
is made up of the brain and spinal cord and contains the majority of nerve cells and synaptic 
connections. It sends and receives sensory info to and from the Peripheral Nervous System (PNS) 
via sensory and motor cells.  The CNS is responsible for receiving, processing and transmitting 
information by means of electrical and chemical interactions. 
 
3.2.1 Spinal Cord  
The spinal cord is the main pathway which connects the brain and peripheral nervous system 
(PNS).  It is approximately the diameter of a human finger which extends from the brain down 
the middle of the back and is protected by the bony vertebral column.  The Spinal cord consists 
of 31 pairs of spinal nerves consisting of fibres. It is surrounded by cerebrospinal fluid which 
protects the nerves against damage from the vertebral column.  Between the vertebrae the spinal 
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nerves enter the spinal column and join with the spinal cord.  Each junction has a sensory and 
motor connection. The spinal nerves are divided into 4 main groups of nerves which exit at 
different levels of the spinal cord.  In descending order, they range from the cervical nerves 
(nerves in the neck) which supply movement and feeling to the arms, neck and upper trunk and 
also control breathing; the thoracic nerves (nerves in the upper back) which supply the trunk and 
abdomen and lumbar nerves, and sacral nerves (nerves in lower back) which supply the legs, 
bladder, bowel and, sexual organs.   
   
 
Figure 5 The functional area of the brain.  Image taken from Purves et al (2008) 
  
3.2.2 Brain  
The brain is the most complex organ which controls most of the body’s activities, as displayed 
in Fig 5 above.  It is protected by the bones of the skull and by three thin membranes called 
meninges.  It is also protected and cushioned by cerebrospinal fluid.  It is the only organ able to 
produce ‘intelligent’ action based on past experience, present events and, future plans and is 
divided into the hindbrain, midbrain and, forebrain.  The brain processes and interprets sensory 
information sent from the spinal cord.   
The forebrain, (cerebrum) is the largest and most highly developed part of the brain. The 
cerebrum is categorised into areas according to their function - sensory, motor or associative.  It 
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consists of the thalamus, hypothalamus and, two cerebral hemispheres which are joined by the 
corpus callosum (a band of nerve fibres).  The cerebral hemispheres are separated into two halves 
by the sagittal fissure.  They consist of four components; cerebral cortex; basal ganglia’s; 
hippocampus formations and amygdala.  The outer layer of the cerebral hemisphere is the 
cerebral cortex which is made up of grey matter and is responsible for receiving and processing 
sensory information such as decision making, speech, learning, memory and imagination and, 
controlling motor and autoimmune functions.  Most of the information processing takes place in 
the cerebral cortex which is separated into 4 major lobes.  These are the frontal, temporal, parietal 
and occipital lobes.  These are shown in Fig.6 below.   
 
 
Figure 6 The major brain areas and lobes.  Image taken from Purves et al. (2008) 
 
3.2.3 Brain Stem  
The Brain stem is a collective term for midbrain, pons and medulla and is a continuation of the 
spinal cord.  It provides the main motor and sensory innervation to the face and neck via cranial 
nerves and is an extremely important component of the brain as the nerve connections of both 
motor and sensory systems from the brain to the rest of the body pass through it.  The brain stem 
assists in the regulation of respiratory and cardiac function and also forms part of the auditory 
pathway.  
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3.3 Peripheral Nervous System (PNS)  
The Peripheral Nervous System (PNS) connects to various organs and structures of the body 
through cranial and spinal nerves.  It includes all of the nervous system outside the brain and 
spinal cord.  The PNS consists of sensory neurons, and nerves that connect to one another and to 
the central nervous system. There are two types of cells in the PNS which transport information 
to (sensory nervous cells) and from (motor nervous cells) the CNS.  Sensory neurons react to 
physical stimuli such as light, sound and touch and send feedback from the nerves to the central 
nervous system about the body’s surrounding environment. Motor neurons, located in the central 
nervous system or in peripheral ganglia, transmit signals from the brain and spinal cord to muscle 
fibres throughout the body. The PNS is divided into three systems, Autonomic Nervous System 
(ANS), Somatic Nervous System (SNS) and, Enteric Nervous System (ENS).  
 
3.3.1 Somatic Nervous System (SNS)  
The Somatic Nervous System (SNS) is responsible for transporting motor and sensory 
information to and from the CNS and is made up of nerves that connect to the skin, sensory 
organs and skeletal muscles.  Neurons of the somatic system project from the CNS system 
directly into the muscles and sensory organs.  The body of the neurons are situation in the CNS 
and the axons project and terminate in the skin, sense organs or muscles.  Electrochemical 
impulses then travel along the axon to the brain and spinal cord.  The SNS is responsible for 
nearly all voluntary movements as well as the processing of sensory information that arrives via 
external stimuli including hearing, touch and sight.   It consists of spinal nerves which carry 
sensory information into the spinal cord, cranial nerves that carry info in and out of the brain 
stem and association nerves that integrate sensory input and motor output.    
 
3.3.2 Autonomic Nervous System (ANS)  
The Autonomic Nervous System (ANS) is part of the nervous system that controls the functions 
of our internal organs (the Viscera) such as heart, stomach and intestines and also carries signals 
to the involuntary muscles, such as cardiac and smooth muscle.  It has two main parts; The 
Sympathetic Nervous System and Parasympathetic Nervous System which tend to have opposing 
effects.  The sympathetic nervous system is responsible for the ‘fight or flight’ response, in which 
blood pressure and heart rate rise.  The synapse in the sympathetic pre-ganglion neuron use 
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acetylcholine as a neurotransmitter and the synapse between the post-ganglionic neuron with the 
target organ uses a neurotransmitter called norepinephrine.   The parasympathetic nervous system 
tends to act in opposition to the sympathetic nervous system, by slowing down the heartbeat and 
dilating the blood vessels. It regulates the function of many glands, such as those that produce 
saliva and tears, and also stimulates digestive secretions. 
  
3.4 Cranial Nerves   
As previously mentioned, there are a total of twelve bilaterally paired cranial nerves originating 
from the brain and brain stem.  Each of them carries different functions related to different senses 
of body. Apart from sensory functions there are also some that work as motor nerves or mixed 
nerves.  
 
 
Figure 7 Ventral brain showing labelled cranial nerves.  Image taken from WikiCommons (2012) 
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3.4. 1 Trigeminal Nerve  
The trigeminal nerve is known as the 5th (V) and largest cranial nerve.  It contains both sensory 
and motor components.  Fibres carrying general sensory information (touch, pressure, pain and 
temp) from the head enter the brain through the trigeminal nerve at the level of the pons and 
terminate in the trigeminal sensory nucleus.  This is the largest nucleus that runs the whole length 
of the brain stem and extends into the cervical spinal cord.  The trigeminal nerve is responsible 
for general sensation in face and motor functions such as biting and chewing.  Sensory functions 
of the trigeminal nerve are to provide the tactile, proprioceptive and nociceptive inference to the 
face and mouth.  The nerve consists of three major branches, ophthalmic nerve, maxillary nerve 
which are purely sensory and mandibular nerve which consists of both sensory and motor 
functions.    
The mandibular nerve carries touch/position and pain /temp sensation form the mouth.  It is not 
responsible for taste sensation, chorda tympani is responsible for taste but one of its branches the 
lingual nerve carries multiple types of nerve fibres that do not originate in the mandibular nerve.  
The branches intersect on the trigeminal ganglion, which contains the cell bodies of incoming 
nerve fibres.  From the trigeminal ganglion a single large sensory root enters the brain stem at 
the level of the pons and motor fibres pass through the trigeminal on their way to the peripheral 
muscles.   In classical anatomy the trigeminal nerve is said to have general somatic afferent 
(sensory) components, as well as special visceral efferent motor components.   
 
3.4. 2 Vestibularcochlear Nerve   
The vestibularcochlear nerve is the 8th cranial nerve (VIII) and is responsible for transmitting 
sound and equilibrium information from the inner ear to the brain.  It is a sensory nerve along 
which the sensory cells of the inner ear convey information to the brain and consists of two 
component parts, the cochlear nerve carrying information about hearing and the vestibular nerve 
carry information about movement and balance.  Both nerve parts pass through the internal 
acoustic meatus in the temporal bone which also contains the facial nerve and attach to the brain 
stem.    
 
The cochlear nerve fibres make contact with the hair cells in the organ of Corti within the cochlear 
duct of the inner ear.  The cell bodies of these fibres are known as the spiral ganglion.  These 
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fibres end in the dorsal and ventral cochlear nuclei and the next stage of neural processing in the 
auditory system begins.    
  
3.5   Auditory System  
 
Figure 8 Principal ascending connections of the auditory component of the vestibulocochlear nerve. 
Image taken from Kandel et al. (2000) 
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3.5.1 The Auditory System 
The auditory system is a sensory system which is responsible for the sense of hearing and is 
divided into the peripheral auditory system and central auditory system as shown in Fig.7. The 
peripheral system which shall be discussed further in Chapter Four consists of the outer, middle 
and inner ear which performs mechanoelectrical transduction of sound pressure waves into neural 
action potentials.  This is the first stage of sound transduction which feeds directly into the 
nervous system.   The re-encoded sound travels down the vestibulocochlear nerve to the central 
auditory system which consists of the cochlear nuclei, trapezoid body in the ventral pons, superior 
olivary complex (SOC) of the brain stem, lateral lemniscuses in the brainstem, inferior colliculus 
(IC) of the midbrain, medial geniculate nucleus and the primary auditory cortex which is the first 
region of the primary auditory cortex to receive auditory input as shown in Fig. 7 above.  
 
3.5.2 Dorsal Cochlear Nucleus  
The cochlear nucleus (CN) is the first synapse or relay point in the auditory system and receives 
information directly via the 8th nerve and somatosensory input indirectly from the 5th nerve via 
granule cells.  Auditory signals go through the CN on their way to the auditory cortex for further 
processing via the cochlear nerve.  It is split anatomically and physiological into 2 regions, the 
dorsal cochlear nucleus (DCN) and ventral cochlear nucleus (VCN).  The CN receives auditory 
signals from the hair cells in the cochlea, where sound is detected, as well as signals related to 
eye movements.  It also receives signals from muscle position sensors and relays these to other 
areas of the brain.  Sensory data from muscles and acoustic data from the ears are both relayed 
to the brain at very nearly the same point in the brain stem.  The cochlear nucleus receives input 
from each spiral ganglion, but also receives input from other parts of the brain, such as auditory 
cortex, pontine nuclei, trigeminal ganglion and nucleus, dorsal column nuclei and the second 
dorsal root ganglion. The inputs from these other areas of the brain probably play a role in sound 
localisation.  It is also believed that the DCN plays a role in tinnitus perception, which will be 
discussed in more detail in Chapter Five.  
 
3.5.3 Superior Olivary Complex   
The superior olivary complex (SOC) is the second major relay in the brain stem.  Located 
in the pons, on either side of the brain, it is tonotopically organised and receives projections 
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from the ventral cochlear nucleus (VCN) and the dorsal cochlear nucleus (DCN) via the 
ventral acoustic stria.  The nuclear complex can localise sound in acoustic space by 
discriminating the differences between the intensity of sound to each ear or in the timing of 
sounds arriving at the ear.  They have an inhibitory function and monitor the transmission 
of auditory information to the cochlear nerve.   
 
3.5.4 Lateral Lemniscus  
Ascending fibres comprise the lateral lemniscus which, carry information regarding sound from 
the central nuclei to various brain stem nuclei and contralaterally to the inferior colliculus (IC) 
of the mid brain.    
 
3.5.5 Inferior Colliculus (IC)  
The dorsal portion of the inferior colliculus (IC) receives projections from the neurons that 
respond to low frequencies of sound, as opposed to the ventral portion which responds to high 
frequencies of sound.  The auditory information is then processed and relayed by the IC to the 
medial geniculate nucleus (MGN) of the thalamus.    
 
3.5.6 Thalamus   
The thalamus sits deep in the brain on top of the brain stem, between the cerebral cortex and 
midbrain.  It is an area which carries out the first basic sorting of incoming impulses and directs 
them to the different parts of the cerebrum.  It also directs some outgoing impulses.  It is one of 
four main parts of the diencephalon, and connects to the hippocampus via the mammillo-thalamic 
tract.  It has multiple functions, and is mainly thought to act as a relay between a range of 
subcortical areas and the cerebral cortex.  It is the largest part of the diencephalon and plays an 
important role in cognitive, sensory and motor functions.  Apart from the olfactory system, every 
sensory system includes a thalamic nucleus that receives sensory signals and sends them to 
primary cortical areas. The medial geniculate nucleus (MGN) which is tonotopically arranged 
acts as a key auditory relay between the inferior colliculus (IC) of the midbrain and the primary 
auditory cortex of the temporal lobe.  It relays precise information about frequency, intensity and 
binaural properties of sound.  It is the gateway to the cerebral cortex as nearly all sensory inputs 
pass through it to the higher levels of the brain.  
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3.5.7 Primary Auditory Cortex   
The auditory cortex is divided into three main parts, primary secondary and tertiary cortices with 
the primary being located between the two others.  It is comprised of two areas named Brodmann 
areas 41 and 42, which together are referred to as the A-1 region.  The human primary auditory 
cortex is located on the superior part of the temporal lobe just above the ear.  It is responsible for 
processing signals from the auditory sensory system and is believed to be mainly responsible for 
processing the more simple elements of sound, such as pitch in comparison to the secondary 
auditory cortex which is believe to process more complex sounds such as rhythmic patterns. It 
does not function in isolation but interacts with other cortical and neocortical structures and 
receives projections directly from the medial geniculate nucleus. Like most of the ascending 
auditory structures, it is characterised by its tonotopic organisation which arises in the cochlea 
and is maintained throughout the auditory system (Truex & Carpenter, 1969; Aldhafeeri, 2012).     
  
Auditory information is further processed and interpreted in the auditory association cortex. Part 
of the temporal lobe is curled inwards and forms the hippocampus which is part of the limbic 
system.  It main function is in relation to memory and emotional behaviour.  The amygdala which 
is also part of the limbic system lies close to the anterior end of the hippocampus.  The amygdala 
receives sensory information from the various sensory modalities, including the auditory, 
somatosensory, visual and olfactory stimuli.  The amygdala is anatomically and functionally 
connected to brain regions which include; the basal forebrain, hypothalamus, hippocampal 
formation and striatum.   
This will be further discussed in Chapter Five.  
  
3.6 Somatosensory Cortex   
The postcentral gyrus of the parietal lobe is referred to as the somatosensory cortex.  It processes 
input from various regions of the body which are sensitive to touch, pressure, pain, itching, 
proprioception and temperature.  It is located next to the motor cortex and both are quite similarly 
organised in terms of their functional relation to various body parts.  The cortex processes 
information contralaterally.  Impulses from the body associated with sensation of pain, temp etc. 
run across nerves to the thalamus which passes the signals to the somatosensory system.   The 
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cortex receives afferents from the ventral posterior nucleus of the thalamus, which is when the 
spinothalamic tract, trigeminothalamic tract and medial lemnisucs terminate. The somatosensory 
cortex has also the ability to reorganise or rewire itself in response to external events, this is 
known as neuroplasticity.  Behind the cortex lies the sensory association cortex which is 
responsible for interpreting general sensory information.   
 
An area that resides between the somatosensory, visual and auditory association areas is referred 
to as the common integrative area.  It is thought to be involved in the integration of signals from 
all these areas, as well as from the olfactory and gustatory areas, the brain stem and thalamus 
(Crossman & Neary, 2010).   
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CHAPTER FOUR: NEURAL PATHOLOGIES 
  
Chapter Four gives a brief overview of the auditory system and the mechanoelectrical 
transduction of sound pressure into neural action potentials. We pay particular attention to the 
human sense of hearing, the relationship between tinnitus and high frequency hearing loss, and 
neural pathologies in the central nervous system which drive neuroplasticity.    
  
4.1 Peripheral Auditory System   
 
Figure 9 The Peripheral Auditory System.  Image taken from E.R. Kandel et al. (2000) 
 
4.2.1 Outer Ear  
The outer ear consists of the pinna, a flexible oval shaped structure attached to the ear, and the 
ear canal or meatus, which leads to the middle ear, see Figure 8 above.  Before sound reaches the 
middle ear it is picked up by the outer ear.  The pinna is responsible for funnelling sounds into 
the ear canals.  Sound travels along the ear canal, and causes the eardrum to vibrate.  The human 
ear can comfortably perceive mechanical disturbances in the air in the amplitude range of 0dB to 
80dB and in the frequency range of 20Hz to 20 kHz. 
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4.1.2 Middle Ear  
This vibration is passed through to the tiny bones of the middle ear known as the ossicles; these 
include the malleus, incus, and stapes which are responsible for amplifying sound and 
transmitting vibrations to the inner ear.  Two muscles in the middle ear, the tensor tympanic 
which is supplied by a branch of the trigeminal nerve and the stapedius muscle which is supplied 
by the facial nerve, are responsible for reducing transmission of some sounds.   The middle ear 
is filled with air and the pressure on each side of the eardrum needs to be similar so that the 
eardrum can vibrate correctly. The Eustachian Tube (ET) is responsible for equalising pressure 
in the middle ear, it connects the middle to the back of the throat and pressure is normally 
maintained by swallowing as this opens and closes the tube.  The middle ear also contains the 
oval and round windows which are miniature versions of the eardrum and separate the middle 
ear from the inner ear.   
  
4.2.3 Inner Ear  
The inner ear is where sound is converted to mechanical energy and then to nerve impulses which 
travel to the brain.  It consists of a spiral fluid-filled cochlea which contains the organ of Corti, 
the most important component of hearing which contains receptors of hearing called stereocilia.   
The Corti sits in the Basilar Membrane, which is a very sensitive membrane (Ballantyne et al., 
1993:24-44).  Sounds of different frequencies cause different parts of the membrane to vibrate.  
The basilar membrane of perilymph is compressed inwards by the movement of the stapes.  When 
the basilar membrane vibrates, the stereocilia and small sensory hair cells inside the Corti begin 
to move.  The organ of Corti pivots in response to the movements of the basilar membrane, see 
Fig. 9 below.  
   
4.2 Central Auditory Pathway  
The human cochlea is a tonotopically-organised structure that decomposes complex sounds into 
a collection of frequency components which are neutrally encoded and transmitted centrally 
through the auditory nerve.  Situated at the end of the hair cells are tips of nerve fibres.  As hair 
cells are bent, nerve impulses are stimulated in the nerve fibres.  These nerve fibres together make 
up the auditory nerve.  Nerve pulses are transmitted from the ear to the brain via auditory nerves, 
one of the several sensory nerves which are part of the group of nerves known as the cranial 
 37  
  
 
 
nerves.  The re-coded sound travels along the vestibulocochlear nerve through the cochlear nuclei 
which is the first sign of neuronal processing from the inner ear.  The cochlear nuclei are 
anatomically and physiologically split into the dorsal cochlear and ventral nucleus.   The cochlear 
nucleus is thought to sharpen features of the now highly compressed signal.    
  
Neural information continues to the superior olivary complex (SOC) of the brainstem which is 
responsible for lateralisation of sound sources, and onto the inferior colliculus (IC) of the 
midbrain, being further processed at each point. Information reaches the thalamus and is relayed 
to the cortex.  The primary auditory cortex interacts with the secondary auditory cortex which 
surrounds it. The secondary areas interconnect with further processing areas in the superior 
temporal gyrus, in the dorsal bank of the superior temporal sulcus, and in the frontal lobe, which 
are individually important for speech perception as well as  for distinguishing between speech, 
music, and noises.    
  
 
Figure 10 Innervation of the Organ of Corti.  Image taken from E.R. Kandel et al. (2000) 
 
The auditory sensory hair cells are the focal point of the hearing mechanism (Ballantyne et al., 
1993:36).  Sensory-neural hearing loss tends to occur when there is damage to the inner ear, or 
the nerve pathways.  Sensori-nerual hearing-loss is most commonly characterized by a high-
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frequency loss that may involve loss of both outer hair cells (OHC) and inner hair cell (IHC) 
function.  OHC, which are controlled by the olivocochlear efferents, are believed to provide 
dynamic range compression by modulating cochlear amplification gain within the associated 
frequency-bands Guinan (1996).  IHC mechanically transduce the associated frequency 
component and neutrally encode it by modulating the stochastic firing rates of the auditory nerve 
fibres that innervate them, where there is a linear relationship between stimulus intensity and 
firing rates (Kiang, 1975). Loss of OHC function results in a loss of dynamic range compression 
within the associated band, while loss of IHC function results in loss of general sensitivity within 
the band.    
  
4.3 Hearing Loss Related Tinnitus  
As discussed in Chapter One, hearing loss related tinnitus is the most common form of the 
condition and is currently considered untreatable (Eggermont, 2006).  There is a clear relationship 
between tinnitus and high frequency sensorinerual hearing loss (Eggermont & Roberts, 2004; 
Moore et al., 2010; Davis & Rafaie, 2000; Henry & Wilson, 2001) in particular age related 
(Vernon & Meikle, 2000) and noise related (Axelsson & Prasher, 2000) with the pitch of the 
phantom sound often correlating to the frequency of the hearing loss (Norena et al., 2002).  
Although many areas along the auditory pathway have been linked to tinnitus generation (Weisz, 
2007; Wei et al., 2010) it believed that damage to the peripheral organ (cochlea) is the trigger 
point and generation occurs in the central nervous system (Jastreboff, 1990; Schaette & Kempter, 
2006).  Noise induced tinnitus has been reported to correlate with increased activity in many 
auditory regions, from the dorsal cochlear nucleus (DCN) to the cortex (Norena & Eggermont, 
2003; Finlayson & Kaltenback, 2009; Shore et al., 2008). This hyperactivity is thought to occur 
due to the reduced auditory nerve activity which performs an inhibitory role in the auditory brain 
stem structures.  Reduced or degraded peripheral input is believed to be associated with increased 
neuronal activity, increased synchronicity and functional reorganisation in the auditory cortex 
(Norena & Eggermont, 2003; Weisz, 2007; Eggermont & Roberts, 2004; Seiki & Eggermont, 
2003; Moller, 2007).   
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4.4 Central Gain Adaptation   
Jastreboff (1990) suggested that damage to the peripheral organ serves as a trigger for tinnitus 
which is sustained by events occurring in the central auditory pathway (Saunders 2007). This 
‘deafferentation’ subsequently leads to reorganization of tonotopic maps as the effected neurons 
begin to express the tuning preference of frequencies adjacent to the partial hearing loss (Dietrich 
et al. 2001) altered firing rates and synchronicity.  It is believed that this may be driven by a 
‘central gains’ phenomenon that seeks to preserve mean firing rates and neural homeostasis 
(Norena, 2011; Schaette & Kempter, 2006) at the expense of perceptual accuracy. In order to 
compensate for loss of input and normalise the wider frequency response, the central auditory 
system naturally adapts frequency dependent gains within the affected bands.  This mechanism 
is also consistent with the finding that unilateral cochlear implants generally reduce contralateral 
tinnitus (Quaranta et al 2004).  
  
Schaette (2006) also refers to a computational model of this “central gain mechanism”, 
suggesting that reduced cochlear compression increases the required natural gain adaption and 
Parra and Pearlmutter (2007) similarly reports that tinnitus patients are more likely to exhibit 
such frequency-dependant gains.  
  
4.5 Zwicker Tone  
The Zwicker tone which was discovered by Eberhand Zwicker is an auditory illusion similar to 
tinnitus and therefore cannot be explained by known properties of the auditory periphery alone 
(Zwicker, 1964). In their 2006 study, Parra and Pearlmutter proposed a model of central gains 
that seeks to compensate for loss of outer hair cells (OHC) dynamic range compression.  They 
demonstrated that individuals with tinnitus exhibit independent gain control in frequency-bands 
of significant hearing loss.  They postulated that the auditory mechanisms increase internal gains 
when confronted with silence in selected frequency bands which then amplify neuronal noise to 
the point that it is perceived as phantom sounds such as Zwicker tones.    
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Figure 11 Model of Central Gains through laterally increased excitation and decreased inhibition. 
Image taken from Dominguez et al (2006) 
 
4.6 Lateral Inhibition  
Dominguez et al. (2006) describes a theoretical model of decreased lateral inhibition and 
increased lateral excitation in thalamocortical afferents that could underlie such ‘central gains’ 
and may give rise to the illusory perception of tinnitus, as shown in Fig. 10.  
  
Roberts et al. (2010) refers to high frequency, hearing loss and the cortical neurons which start 
to respond preferentially to frequencies at the edge of normal hearing, which as a result become 
overrepresented in the cortical tonotopic map (Eggermont & Komiya, 2000).  This reorganisation 
of the tonotopic map has been detected in human tinnitus sufferers by neuromagnetic braining 
imaging (Roberts et al., 2010). Loss of input to the auditory cortex from peripheral ototrauma 
can also lead to areas of missing frequencies in the cortical tonotopic map (Lockwood et al., 
2002; Moller, 2006).  Our understanding of tonotopic remodelling in the auditory cortex comes 
from the somatosensory system where there is a well-known response to the elimination of 
peripheral input (Salvi et al., 2000).  
  
Animal studies have shown that when a region of the tonotopic map is disconnected from the ear 
by cochlear damage, this region reorganises itself as the affected neurons begin to express the 
tuning preference of their neighbours (Roberts, 2011; Eggermont & Komiya, 2000).  The lost 
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sideband inhibition model proposed by Dominiguez et al. (2006) suggests that spectral 
modification or enrichment of auditory input may compensate for peripheral loss and reverse 
these central gains in the affected frequency bands.  Norena & Eggermont (2006) examined these 
effects of such spectrally modified sound in felines after induced hearing loss and found that 
those which were kept in high frequency enriched environments did not develop the neural 
correlates of tinnitus.   Tonotoptic maps, spontaneous firing rates and synchrony remained 
unchanged post hearing-loss.  Similar studies suggest that sound enrichment may reverse such 
neural pathologies in humans (Stracke et al., 2010; Okamoto et al., 2010).  Hearing aids and other 
sound therapies are used to treat tinnitus patients on this basis (Moffat, 2009), yet questions 
remain about their efficacy (Hobson et al., 2010); Roberts et al., 2008).   
  
4. 7 Neuroplasticity  
Neural plasticity refers to the brains ability to adapt its neural networks on the basis of new 
experience.  The brain has the ability to constantly optimise itself, reorganise itself and transfer 
cognitive abilities from one lobe to the other, particularly as we age.    
  
Neuroplasticity may be “adaptive or positive” in terms of learning or memory allowing us to 
adapt to changes in the environment.   It can also be “negative or maladaptive” resulting in an 
imbalance in excitatory and inhibitory events in the brain resulting in neural hyperactivity 
(Kaltenbach et al., 2005; Saunders, 2007).  
  
Maladaptive neuroplasticity can be seen in various pathologies such as limb amputation and focal 
hand dystonia.  The somatosensory cortex is not expected to respond to any stimulus following 
amputation of a limb and damage to the neural networks; however neighbouring neural inputs 
are believed to be able to stimulate this particular area of the brain and is recognised in the 
affected somatosensory cortex.  The brain compensates for damage by reorganising and forming 
new connections between intact neurons (O’Neill, 2008).   
Deprivation of input to the nervous system is the main factor that can activate neuroplasticy.  
Many studies agree that neuroplasticity plays a major role in the tinnitus pathogenesis (Baguley, 
2002; Eggermont, 2003; Moller, 2003; Eggermont, 2005).  Kaltenbach et al. (2005) describes 
tinnitus as a perceptual manifestation of plastic changes that result in neural hyperactivity.  
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Following hearing loss, the area of missing frequencies reappears in the reorganised tonotopic 
map (Saunders 2007) and it is has been conjectured that tinnitus occurs due to this reorganisation.  
In other words, the brain rewires itself due to the brain cells being deprived of acoustic 
stimulation.  It is also believed that neuroplasticty may be involved in the disorders that often 
accompany tinnitus, such as hyperacusis, phonophobia and depression (Nelson & Chen, 2004; 
Cacace, 2003).  
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CHAPTER FIVE: AUDITORY-SOMATOSENSORY 
INTEGRATION AND IMPLICATIONS FOR THE 
TREATMENT OF TINNITUS 
  
Chapter Five discusses the anatomical and functional links between the auditory and 
somatosensory systems.  We explore these cortical and subcortical links, how they influence the 
perception of sound, and their implications for the treatment of tinnitus.  Finally, we propose a 
novel treatment that utilises auditory-somatosensory interactions.  
  
5.1 Subcortical Auditory-Somatosensory Interaction  
There is long-established evidence of auditory-somatosensory integration in the midbrain 
structure known as the inferior colliculus (IC) and in the brainstem structure known as the 
superior olivary complex (SOC) (Aitkin et al., 1978; Eliades & Wang 2003; 2005). However, 
more recent studies have shown that the subcortical auditory structure with perhaps the greatest 
levels of somatosensory interaction is the cochlear nucleus (CN).  The CN receives input from 
the ipsilateral auditory nerve (8th nerve), from the contralateral nucleus and also from trigeminal 
sensory structures (Shore et al., 2000; Zhou & Shore 2004; Shore & Zhou 2006).  It is believed 
that the trigeminal projections are associated with systems that control vocalisation, chewing and 
breathing (Shore & Zhou, 2006).  Furthermore, it has been shown that electrical stimulation of 
these projections can suppress acoustically driven activity in CN and IC.  It has been suggested 
that the function of these anatomical and physiological auditory-somatosensory connections are 
to suppress responses to endogenous sounds, such as vocalisations, chewing and breathing 
relative to responses to more exogenous sounds (Shore & Zhou, 2006).  
  
The involvement of the dorsal cochlear nucleus (DCN) has been implicated in the generation of 
the illusory sounds of tinnitus.  In addition to changes observed in the peripheral hearing systems, 
neural hyperactivity has been observed in the DCN following hearing loss (Kaltenbach et al., 
2005, Sachaete & Kempter. 2008). It is believed that this is a neural correlate of the ‘central 
gains’ phenomenon discussed in Chapter Four.  It is unclear what contribution, if any, 
somatosensory inputs into the DCN make to the generation of this neural hyperactivity.  
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However, it has been suggested that somatosensory inputs are relayed to DCN neurons via a 
series of excitatory fibres, which may contribute to increased neural activity (Levine, 1999; 
Weinberg, 1987; Eggermont & Roberts, 2004; Brozoskin & Bauer, 2005; Shore, 2005).  Shore 
et al. (2006) found that tinnitus percepts may be qualitatively and quantitatively modulated 
through physical manipulation of the head, neck and jaw and proposed a model, which suggests 
this modulation is the result of complex auditory-somatosensory spike timing. Tzounopoulos 
(2004) suggested that these auditory-somatosensory interactions drive synaptic plasticity in the 
DCN that could underlie the ‘ignition’ and ‘maintenance’ of tinnitus.  Conversely, Shore et al. 
(2006) demonstrated that auditory evoked activity in DCN neurons can be suppressed by 
electrically stimulating the trigeminal system.  Harnessing the trigeminal capability to suppress 
sound through electrical stimulation may be the basis for a novel technological intervention for 
tinnitus, which we will discuss in further detail in Section 5.5.  This hypothesis is supported by 
promising findings in human studies that electrically stimulated the C2 dermatome using 
Transcutaneous Electrical Nerve Stimulation (TENS) (Vanneste et al., 2010).  
  
5.2 Cortical Auditory-Somatosensory Interaction  
There is a growing body of evidence of cortical-level auditory-somatosensory integration. Brain-
imaging studies with primates have shown that auditory broadband sound combined with tactile 
stimulation of the hand elicited auditory-somatosensory integration in the area posterior to and 
along the lateral side of the primary auditory cortex in the caudal auditory belt (Kayser et al., 
2005).  Similar studies with humans showed enhanced auditory cortical responses to 
somatosensory stimuli in hearing-impaired humans (Auer et al., 2007).  Perhaps the most well-
known example of auditory-somatosensory integration is the ‘Parchment Skin Illusion’ 
(Jousmaki & Hari 1998), which shows that sound strongly, modulates tactile sensations.  
Similarly, touch has been shown to have a corresponding influence over auditory sensations.  
Studies showed that simultaneous vibrotactile stimulation attenuates loudness perception in 
normal hearing adults (Schurmann et al., 2004). Similar studies showed that simultaneous audio-
tactile stimuli bias the perceived location of sounds (Caclin et al., 2002). Furthermore, animal 
studies demonstrated that simultaneous audio-tactile stimuli can alter the frequency responses of 
rodent and chiropteran cortical, collicular and corticofugal neurons for periods longer than 
twenty-four hours (Gao & Suga, 2000; Kilgard & Merznich, 1998; Bao et al., 2001). Weinberger 
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(1998) postulates that auditory and somatosensory stimuli are associated in the medial division 
of the medial geniculate body (MGB) and intralaminar nucleus and that the associated signal is 
sent to the basal forebrain via the amygdala. The basal forebrain plays a critical role in the 
production of acetylcholine, which has been shown to improve cortical information processing 
and enhance conditioned learning (Kuo, 2007; Laviolette & van der Kooy, 2004; Changeaux, 
2010).  This hypothesis was experimentally verified in animal studies that used simultaneous 
audio tones and electrical vagus nerve stimulation to reverse the neural correlates of tinnitus in 
rodents (Engineer, 2011).   
 
 
Figure 12 Working Hypothesis for the Adjustment and Improvement of Auditory Signal Processing according to 
Associative Learning (Auditory Fear Conditioning). Image taken from Suga et al. (2002) 
 
The findings that audio-tactile stimuli can modulate the frequency and loudness of auditory 
perception constitutes a compelling and growing case for the multisensory approach to treating 
tinnitus.  In the following sections, we will discuss the optimal forms of sound and tactile 
stimulation that might form the basis for such a multisensory treatment.   
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5.3 Auditory Stimuli   
5.3.1 Tonal Stimuli  
Tonal stimuli have been widely used in both unisensory and multisensory tinnitus interventions.  
In animal studies, tones have been used in combination with simultaneous electrical stimulation 
of the cutaneous surface of the foot to alter the frequency responses of rodent and chiropteran 
cortical, collicular and corticofugal neurons for periods longer than twenty-four hours (Gao & 
Suga, 2000; Kilgard & Merznich, 1998; Bao et al., 2001).  Similarly, simultaneous audio tones 
and electrical vagus nerve stimulation have been used to reverse the neural correlates of tinnitus 
in the auditory cortices of rodents (Engineer, 2011).  Tones have also been used to disrupt cortical 
synchrony in the auditory cortices of humans (Tass et al., 2012).    
  
While the use of tonal stimuli shows promising results in animal and human research, the 
practical clinical use of such stimuli faces major challenges. The repetitive mechanistic nature of 
the sounds are unlikely to be well tolerated by patients in the long-term and may even further 
contribute to tinnitus related stress.  
 
5.3.2 Sound Enrichment  
The lateral inhibition model proposed by Dominguez et al. (2008) and frequency dependent 
central gains model proposed by Parra & Pearlmutter (2007) suggest that spectral modification 
or enrichment of auditory input may compensate for peripheral loss and reverse central gains in 
affected frequency bands. Norena & Eggermont (2006) examined the neurologic benefit of 
introducing sound enrichment immediately after high-frequency hearing loss was induced in 
felines and found that animals that were kept in high-frequency enriched environments did not 
develop neural correlates of tinnitus. Tonotopic maps, spontaneous firing rates and synchrony 
remained unchanged post-hearing-loss. Similar studies suggest that sound enrichment may 
reverse such neural pathologies in humans a priori (Stracke et al., 2010; Okamoto et al., 2010). 
Hearing aids and other sound therapies are used to treat tinnitus patients on this basis (Saltzman 
& Ersner, 1947; Surr et al, 1985; Moller et al., 2011; Melin et al., 1987; Moffat, 2009; Roberts 
et al., 2008; Hobson et al., 2010).    
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Hearing aids are widely used and are generally well tolerated by patients.  Modern digital hearing 
aids adjust amplification in independent frequency bands according to the patient’s audiogram.  
Sound is amplified in bands where there is a loss and not amplified in bands where hearing is 
normal.  This approach should theoretically compensate for frequency-dependent peripheral 
losses and thus alleviate the resulting central gains phenomenon.   
  
The practical clinical experience of digital hearing aids is that many patients find the lack of 
dynamic compression frustrating, especially when moving from noisy to quiet environments.  
Patients often begin to manually adjust amplification levels to suit their environment thus 
negating the settings made by their audiologist and undermining any derived therapeutic benefit 
for their tinnitus.  
  
5.4 Tactile Stimuli  
5.4.1 Trigeminal Stimulation  
As discussed in Section 5.1, studies have shown that electrical stimulation of the trigeminal 
system can suppress acoustically-driven activity in the cochlear nucleus (CN) and inferior 
colliculus (IC). Shore et al. (2006) demonstrated that when acoustic tones were preceded by 
electrical pulses delivered to the trigeminal nerve, the DCN responses to the acoustic tones were 
suppressed.  Furthermore, Tzounopoulos (2004) suggested that these auditory-somatosensory 
interactions drive synaptic plasticity in the DCN.   
 
This inhibitory mechanism could potentially be harnessed through broad transcutaneous 
electrical stimulation of the trigeminal system (Opthalmic, Maxillary or Mandibular) or through 
more subtle auditory-trigeminal stimuli that utilise pulse/tone timing to manipulate DCN 
plasticity.    
  
Auditory-trigeminal pulse/tone timing is technically challenging and currently not well 
understood in humans.  This approach would require extensive further research to determine the 
latencies of the human trigeminal and auditory systems and is beyond the scope of this project.    
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Broad trigeminal stimulation has the advantages of being technologically and clinically practical 
and its use is supported by the findings of studies using transcutaneous electrical stimulation of 
the C2 dermatome to treat tinnitus (Vanneste et al., 2010).  As previously mentioned in Chapter 
Four, TENS is a very safe, non-invasive method, and a method used to reduce pain (Herraiz, 
2007; Vanestte & De Ridder, 2012).  For tinnitus, it was initially shown that TENs of the median 
nerve could modulate tinnitus perception in a number of patients (Moller et al., 1992).  A number 
of clinical studies have been conducted over the years to investigate the use of electrical 
cutaneous stimulation as a potential treatment for tinnitus (Dobie, 1986; Thedinger, 1987; 
Shulman, 1987; Vanneste, 2010; Engelberg & Baucer, 1985; Steenerson, 2003; Herraiz, 2007; 
Kapkin, 2008).  These studies focussed on the stimulation of the inhibitory inputs of the 
trigeminal nerve into the dorsal cochlear nucleus through surface electrodes.  In a recent study 
by Vanneste et al. (2011) it was shown that there is variability in the response to TENS as well 
as tDCS and TMS.  Based on such results it is argued that TENS only modulates the tinnitus 
brain circuit indirectly via the C2 nerve, activation of which modulates signal transmission in the 
dorsal cochlear nucleus, whereas TMS and tDCS have a dual working mechanism, a TENS-like 
indirect mechanism via somatosensory influences mediated through the C2 and/ or the trigeminal 
nerve plus a direct brain modulating mechanism.  There is evidence that electrical stimulation 
works for some patients and although there are reports of some minor adverse effects, (Theringer, 
1987; Steerenson, 2003), other studies report of continued tinnitus treatment after electrical 
stimulation (Steenerson, 2003; Engleberg, 1995).  
 
5.4.2 Paired Stimulation  
As discussed in Section 5.2, brain-imaging studies have shown enhanced auditory cortical 
responses to somatosensory stimuli (Kayser et al., 2005; Auer et al., 2007).  It has been suggested 
that these enhanced cortical responses may be due to elevated cholinergic activity Kuo (2007); 
Laviolette & van der Kooy (2004); Changeaux (2010) resulting from limbic system and basal 
forebrain engagement triggered by multisensory stimuli (Weinberger, 1998).  The cutaneous 
surface of the hands or feet are the preferred non-invasive stimulation sites for the vast majority 
of paired stimulation studies (Kayser et al. 2005; Auer et al. 2007; Schurmann et al. 2004; Gao 
& Suga, 2000; Levanen, 1998).    
  
 49  
  
 
 
Another stimulation site that has been used in vestibular prosthesis studies is the mucosal surface 
of the tongue (Tyler et al., 2003). The anterio-dorsal surface of the tongue is an optimal site for 
stimulation for the following reasons:  Firstly, the tongue is a mucosal surface, which is beneficial 
because it does not have an electrically impeding epidermal layer and it is coated with a 
replenishing electrolyte (saliva) that enhances transcutaneous electrical stimulation.  Secondly, 
the anterio-dorsal surface of the tongue possesses one of the highest somatic nerve densities in 
the human body and as a result has a disproportionately large representation in the somatosensory 
homunculus.    Finally, the lingual branch of the trigeminal nerve innervates the anterior surface 
of the tongue. Shore et al. (2006) demonstrated that there are important anatomical and functional 
links between the trigeminal nerve and central auditory structures, such as the cochlear nuclei.  
To date there has been no publications covering the effects of electrical stimulation delivered via 
the tongue.  However, a purpose-designed tongue stimulator, the BrainPort (Wicab) have been 
used to treat vestibular balance disorders (Tyler et al., 2003).  This device is connected to a tilt-
sensor on the head, and produces error signals to the left or right of a central band if the head 
position control deteriorates.  Significant balance improvements have been reported using this 
modality (Tyler et al., 2003).   
  
More invasive approaches to paired stimulation have included vagus nerve stimulation (VNS) 
and deep brain stimulation of the basal forebrain (Engineer, 2011; Kilgard & Merznich, 1998).  
While these approaches showed promising results, they are unlikely to be clinically adopted 
given their highly invasive nature.  
   
5.5 Hypothesis   
Tinnitus interventions can be broadly categorised into top-down and bottom-up approaches.  
Top-down approaches seek to reverse cortical-level correlates of tinnitus, such as altered 
characteristic frequency responses, hyperactivity and synchronicity, in the belief that 
corticoefferent mechanisms will propogate recovery caudally. Examples of such top-down 
approaches were discussed Section 5.3, where tones paired with electrical stimulation pulses on 
the foot were used to alter the characteristic frequencies of cortical and corticofugal neurons (Gao 
& Suga, 2000; Kilgard & Merznich, 1998; Bao et al., 2001).  Other similar approaches utilised 
paired tone / pulses targeting the Vagus nerve to alter characteristic frequencies of cortical 
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neurons (Engineer, 2011) and demonstrated promising results in reversing cortical correlates of 
tinnitus.    
   
Bottom-up approaches seek to address the underlying cause of tinnitus, such as sensory 
deafferentation or sensori-neural hearing loss, in the belief that afferent mechanisms will 
propagate recovery dorsally.  Examples of such bottom-up approaches were discussed in Section 
5.4, where deficits in affected frequency bands were addressed through sound amplification.  
Studies using sound enrichment to compensate for deficient frequency bands demonstrated 
promising results in preventing the onset of tinnitus correlates (tonotopic reorganisation, 
spontaneous firing rates, synchrony) (Norena & Eggermont, 2006) and in reversing them (Stracke 
et al., 2010; Okamoto et al., 2010).  
  
We postulate that paired tone / pulse approaches, while useful in demonstrating the principle that 
auditory-somatosensory stimuli can alter characteristic frequencies of cortical neurons, face a 
number of fundamental challenges:  
 
• Multiplexing – most paired tone / pulse approaches involve permutations of many 
independent frequency tones with a single tactile stimulation point.  Tones must be 
multiplexed with this single simultaneous point in order to tune the characteristic 
frequencies of each of the corresponding neurons.  
• Channel bandwidth maximisation – tones only partially utilise channel bandwidth 
in deficient frequency bands, especially if these tones are multiplexed across many 
bands, as described above.  
  
We propose a novel approach that seeks to address the multiplexing and channel maximisation 
issues highlighted above.  This hypothetical treatment for tinnitus combines band-pass filtered 
acoustic stimuli, where the filter is characterized by the patient’s hearing loss, with simultaneous 
transcutaneous electrical stimulation of the anterio-dorsal surface of the tongue, where the 
electrical stimulus is a spatio-temporal encoded pattern that represents the instantaneous 
frequency-domain coefficients of the auditory stimulus.  Such an approach should theoretically 
reap the benefits of both the top-down and bottom-up approaches described above.   
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The filtered sound compensates for channel deficiencies and ensures channel bandwidth 
maximisation, while the simultaneous electrical stimulus is delivered through an array, such that 
each frequency channel has a dedicated stimulator, thus negating the need for multiplexing.    
  
 We propose that this novel multisensory approach should compensate for peripheral hearing loss 
and thus alleviate central gains, and similarly, elicit enhanced auditory cortical responses and 
alter characteristic frequencies.  In the following chapters, we discuss a prospective pilot study 
to investigate the effect of this theoretical approach on the objective and subjective measures of 
permanent intractable tinnitus.  
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CHAPTER SIX: METHODOLOGY 
  
Chapter Six, provides the general methods of the clinical trial, including recruitment, eligibility 
criteria, trial procedures, outcome measures, data collection and analysis.    
  
6.1 Study Design   
This study was a prospective single arm pilot study.  It was conducted with approval from the 
Research Ethics Committee of NUI Maynooth and The Hermitage Medical Clinic Lucan in 
collaboration with MuteButton Ltd, Nova UCD.  
  
The study was designed to establish ‘Baseline’ values in objective (MML, TLM, TM) and 
subjective (THI) tinnitus measures over the 4-week run-in period and to determine efficacy by 
comparing measured values with those Baseline values over the 10-week treatment and 2-week 
follow-up periods.  A secondary objective was to assess usage and tolerance of the device over 
the duration of the trial.   
  
6.2 Study Objective   
The objective of the study was to determine the impact of acoustic and tactile multi-modal 
stimulation on symptoms of permanent intractable tinnitus as measures by objective and 
subjective measures including Minimum Masking Level (MML), Tinnitus Loudness Masking 
(Tinnitus Loudness Masking), Tinnitus Handicap Inventory (THI) and Visual Analogue Scale 
(VAS).    
  
6.3 Study Duration   
This study was conducted over a 16-week period with 54 patients (34 male, 20 female with a 
mean age of 47 years), suffering from permanent intractable tinnitus (>6 months) and with an 
accompanying high-frequency hearing-loss.   Patients were screened for 4 weeks, they receive 
treatment for 10 weeks and they were followed up 2 weeks post treatment.  For the duration of 
the study they were assessed every 2 weeks in the clinical environment.   
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6.4 Study Supervision   
The study was conducted by a Clinical Audiologist who is registered with the Irish Society of 
Hearing Aid Audiologists (ISHAA) and the Irish Academy of Audiology (IAA), under the 
clinical supervision of a Senior Consultant Otolaryngologist Head & Neck Surgeon who is a 
member of the Association for Research in Otolaryngology, European Academy of Otology and 
Neuro-otology, Royal Society of Medicine: Otology, Laryngology & Rhinology, Prosper 
Meniere Society, Irish Otolaryngology Society and the American Auditory Society.    
  
6.5 Identification of Patients   
Tinnitus patients were referred by ENT Consultants and Audiologist from 4 hospitals in the 
Dublin area; Hermitage Medical Clinic, St James’s Hospital, Tallaght Hospital and Beaumont 
Hospital.  A considerable cohort of tinnitus patients were recruited and screened for participation 
in the research study through the Hermitage Medical Clinic.    
  
6.6 Recruitment and Randomisation and Selection   
Patient recruitment was limited to the greater Dublin. Patients were allocated to the study on 
random basis of attendance at the clinic. Patients were informed that participation in this research 
study was entirely voluntary, and they were free to withdraw from the study at any time without 
having to give a reason.  Their GP was also informed by letter if they were eligible to participate 
in the study (Appendix 1).   
 
6.6.1 Eligibility   
Patient data were deemed eligible if they complied with the following;   
• minimum total use of the device should be 30 minutes per day, i.e. 3.5 hours per 
week   
• the level of stimulus should be greater than zero  
• acceptable timing for visit dates  
• Baseline interview to be conducted within 4 weeks from the start of the new 
treatment  
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6.6.2 Non eligible and withdrawals    
Participants deemed not eligible to take part in this particular study were referred back to their 
GP and advised of further therapies available that may be beneficial.  They also received a letter 
of refusal (Appendix 2).    
  
Any participant who dropped out of this study was analysed according to the intention to-treat 
(ITT) method, i.e. all eligible patients who conducted any part of the study and provided follow-
up data for at least one time-point.  
  
6.7 Patient Selection Criteria  
The eligibility of study participants was determined by inclusion and exclusion criteria, as listed 
below.  
 
6.7.1 Inclusion criteria:  
• Aged <65 years   
• Suffering from subjective intractable tinnitus   
• Tinnitus > 6 months  
• Tinnitus associated with an age or noise related sensory-neural hearing loss  
• Have sound English reading, comprehension and written skills  
• Able and willing to participate in the study for the 16 weeks duration 
• Informed consent 
 
6.7.2 Exclusion criteria:  
• Ulceration of oral cavity or tongue, oral mucosa or significant intra oral disease - to 
mitigate risk of further aggravation these symptoms  
• Meniere’s Disease - due to the fluctuating hearing loss  
• Hyperacusis - to avoid further aggravation of sensitivity of sound  
• Current medical legal cases regarding tinnitus or hearing - in order to avoid any conflict 
of interest  
 
 55  
  
 
 
• Undergoing any treatment for tinnitus - in order to accurately measure the 
independent effect of the intervention 
• Pacemakers - due to potential magnetic interference 
 
6.8 Minimising Bias  
Bias was minimised through anonymised participation and the use of objective and subjective 
internationally recognised outcome measures.   
  
6.9 Assessment of Outcome Measures and Compliance  
Primary outcome measures were assessed across the duration of the study in the clinical 
environment at review visits.  Participant compliance was measured using embedded data 
logging within the tolerability assessed on completion of the study through a questionnaire.   
  
6.9.1 Subjective Outcome Measures  
The Tinnitus Hearing Inventory (THI) was used as the main outcome measure (Appendix 3).  
The THI is a 25-item self-administered questionnaire for the measurement of tinnitus (Newman 
1998).  The THI scoring takes 5-10 minutes, with a score of 4 for a ‘yes’, 2 for ‘sometimes’ and 
0 for ‘no’.  Accordingly results are categorised into 5 main grades of severity from slight, to 
catastrophic (McCoombe, 2001). Participants were also asked to rate the intensity level of their 
tinnitus on a Visual Analogue Scale (VAS) of 10 cm length with 1 being 'barely audible' and 10 
being ‘intolerable’ (Appendix 4).   Participants were given clear instructions and asked to 
complete both the THI and VAS independently every two weeks prior to review visits in the 
clinic waiting area.  
 
6.9.2 Objective Measures  
Participants completed a psychoacoustic assessment, including Tinnitus Matching (TM) which 
determines the frequency and pitch of their tinnitus, Tinnitus Loudness Matching (TLM) which 
determines the intensity of their tinnitus and Minimum Masking Levels (MML) which 
determines the lowest level of noise required to mask the tinnitus.  Participants did not have 
access to the measurements recorded throughout the study. 
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TM and TLM were determined by establishing the frequency level of the tinnitus and the intensity 
level of the tinnitus frequency in the contralateral ear or binaurally if there was no difference 
between both ears.  Both measurements were expressed in Hertz (Hz) and Decibels (dB) 
respectively.  The MML and TLM were determined using 1 dB steps (Henry & Meikle, 2000).  
Participants underwent TM, TLM and MML assessments every two weeks at review visits.  
  
6.10 Treatment  
6.10.1 Pre-Treatment Phase  
Pre-treatment Phase consisted of a four week run-in period prior to commencement of treatment 
where baseline measures were obtained and sampled every 2 weeks at Week 0, Week 2 and Week 
4.  
  
Potential Participants (PP) who expressed an interest in participating in the study and met the 
basic selection criteria were identified and contact via mail, email or phone and given a time/date 
for their first appointment of the pre-treatment phase at the Hermitage Medical Clinic, Dublin 
(Appendix 5). They were sent a copy of the Patient Information Leaflet to read prior to their visit 
(Appendix 6).  PP met with our Medical Advisor (MA) Mr Brendan Conlon, and Principal 
Investigator (PI) Ms Caroline Hamilton who discussed the study in detail and obtained written 
consent (Appendix 7) from participants prior to obtaining baseline measures (screening tests).     
 
Those eligible to participate in the study were subsequently contacted by phone and advised 
within 1-2 weeks after the first initial screening visit and invited to attend a 2nd screening 
appointment.  Following the run-in period, participants were enrolled on the treatment study.    
 
As part of the enrolment appointment, participants were given clear verbal instructions on how 
to use the device as well as instructions regarding maintenance of the device.  They were advised 
to thoroughly read the Information for Use (IFU) and sterilisation instructions prior to leaving 
the clinic.  Under the supervision of both the PI and MA, all participants were instructed to use 
the device for 30 minutes whilst in the clinic.  
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6.10.2 Treatment Phase  
The treatment Phase consisted of a 10 week period were participants were advised to use the 
device for a recommended minimum of 60 minutes per day in their home.  All Participants’ usage 
of the device was logged on an internal SD card.    
 
Objective and subjective tests as described above were carried out at the enrolment visit and 
every 2 weeks for the duration of the study. Patients were given an information pack which 
included details of their appointment dates/times for duration of study (Appendix 8), copy of 
informed consent, copy of information leaflet regarding the study, contact details regarding 
medical issues or adverse effects relating to the device (Appendix 9) and Information for Use 
booklet (Appendix 10).  
  
6.11 Risk Analysis  
Participants were advised to terminate use and to contact the Hermitage Clinic if they 
experienced any side-effects or adverse effects.  They were also instructed to contact a member 
of the research team regarding any device malfunction.    
  
6.12 Materials  
  
Figure 13 The MuteButton device combining spectrally modified sound with simultaneous transcutaneous stimulation 
of the anterior dorsal surface of the tongue.  Image taken from MuteButton (2013) 
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6.12.1 MuteButton Multi-Modal Stimulation Device  
MuteButton is a non-invasive device which combines two existing tinnitus treatment 
approaches, sound therapy and transcutaneous electrical nerve stimulation (TENS) into one 
single treatment, as shown in Fig. 13 above. It simultaneously stimulates the senses of hearing 
and touch using band-pass filtered ‘pink noise’ and random transcutaneous electrical stimulation 
delivered to the tongue.  The centre-frequency of the band-pass filter is set to correspond with 
the frequency of steepest gradient or hearing deficit in the patient’s audiogram.  The patient 
wears the device, (which is approximately the size of an iPhone), using a lanyard around their 
neck and it hangs at the chest area.  It consists of two outputs, a set of headphones and an intra-
oral device.    
 
6.12.2 Headphones  
It involves stimulation in the form ‘pink noise’ played through a set of hi-fidelity headphones 
(Sony model “MDR-XD200) which are placed over the ears.  
 
6.12.3 Intra Oral Device  
Simultaneous to the audio stimulus, tactile patterns consisting of small electrical pulses are 
delivered to the tip of the tongue.  They receive transcutaneous stimulation on the tongue using 
a ‘lollypop’ sensor that sits on the anterior section (tip) of the tongue.  The lollypop is 
approximately 1.5cm2 in surface area and less than a centimetre in profile depth.   It is positioned 
just behind the front teeth, such that the tongue lies against it when the jaws are in a relaxed state 
and lips are closed.  It has 21 transcutaneous electrodes that electrically stimulate the nerve 
endings in the tongue.  The intra-oral device to be used is non-invasive: a tongue-based carbon 
electrode array previously used for sensory substitution, with low voltages and waveforms 
designed to be perceptible but not painful.     
 
6.12.4 Battery  
The device is battery operated and comes with an internal rechargeable battery which is a 
Lithium-Polymer type and a supplied charger (XP Power model VEP08US05) which plugs into 
the socket to charge the battery.    
 
 59  
  
 
 
6.12.5 Micro-SD Card  
A micro-SD card is inserted into the slot on the device.  It contains information relating to the 
specific audio and stimulation patterns that is deemed most suitable for particular tinnitus 
characteristics.  The device will not function if this card is removed or if an alternative card is 
inserted.  It records the hours/days used, volume and audio settings over time.   
 
6.13 Data Collection and Analysis  
6.13.1 Data Collection   
Data was collected during baseline, treatment stage and follow-up stage.  All raw data from the 
THI, VAS and psychoacoustic measures were entered directly into computerised spread sheets.  
After the calculation of weekly means and variances, data were exported to Statistical Package 
for Social Sciences (SPSS, version, 13.0 for Windows) for statistical analysis.    
  
The statistical analysis undertaken in this study can be summarised as follows:  
  
• Establishment of baseline scores: The profile of the patients in the study and the 
severity of their condition.  
• Comparison analysis: The effectiveness of treatment as change from baseline, over 
a period of 16 weeks, in terms of objective and subjective measures  
• Usability and Tolerance: The profile of the usage and tolerability of the device, 
recorded in terms of hours/days used volume and audio settings over time.  
 
6.13.2 Data Analysis  
The data were summarised as mean +/- standard deviations (SD).  Per protocol analysis was 
performed for participants who completed the study.  Data missed was left blank.  In addition, 
participants who dropped out during study were also recorded, and their primary outcome 
measure was analysed using the intention-to-treat analysis.    
 
Boxplots and repeated ANOVA for all visits have been carried out for each score. If overall 
repeated ANOVA shows statistical significance, paired t-test analysis is carried out to compare 
main effect, i.e. change between Baseline V2 (Week 4/1st week of treatment)and V7 (Week 
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14/10th week of treatment), and interim effect, change between Baseline and V4 (Week 8/4th 
week of treatment).  
  
The potential placebo/context effect has been analysed in an exploratory manner. The scores have 
been measured at Screening Visit and at Baseline. This is a 4-week period in which intervention 
is not administered, but some beneficial effect may be observed due to the subjective nature of 
the tinnitus condition. Paired t-tests comparing Screening visit and Baseline are run to test for 
evidence of potential placebo/context effect.  
  
When the probability value was less than 0.05, the difference was considered to be statistically 
significant.   
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CHAPTER SEVEN: RESULTS AND ANALYSIS 
  
Chapter Seven reports on the impact of acoustic and tactile multi-modal stimulation treatment 
for tinnitus and verifies the clinical benefit and user tolerability of the treatment.  
  
7.1 Results and Analysis  
7.1.1 Analysis Population and Compliance  
The statistical analysis was based on all subjects including the intent-to-treat subjects.     
Participant data was deemed eligible if participants met the following compliance and minimum 
appliance requirements.   
• Minimum total use; 30 minutes per day or 3.5 hours per week.  
• Minimum level of stimulus; greater than zero  
• Review visits within one week of scheduled dates  
 
7.1.2 Demographics and Baseline Characteristics  
Baseline measures and basic demographic data (age/gender) were obtained during pre-treatment 
phase. Summary tables and figures are presented below for each characteristic:  
 Age  
Table 1 Age - Summary Statistics  
  Total number  Mean (years)  Std. Dev (years)  Min age (years)  Max age (years)  
Age  54  47  11  21  64  
  
Age Category (years)  Frequency   Percentage (%)  Cum. Percentage (%)  
<30  4  7.41  7.41  
30-39  11  20.37  27.78  
40-49  16  29.63  57.41  
50-59  15  27.78  85.19  
60-69  8  14.91  100%  
Total  54  100%  
  
Table 2 Age – Distribution  
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Average age of the group was 47. The youngest patient was 21 and the eldest is 64. Over half of 
the patients (57%) were under the age of 50.  
 
Gender  
Thirty four (63%) patients were male and 20 (37%) patients were female.  
 
7.1.3 Hearing Loss Profile  
Hearing loss profile was measured for left and right ears individually using GN Otometrics 
Madsen Astera Clinical Audiometer, calibrated in accordance with BS EN 60645-1 (IEC 60645-
1) and the relevant BS EN ISO 389 (ISO 389) series standards.  Hearing loss was classified 
according to severity; Normal, Mild, Mild to Moderate, Moderate, Moderate to Severe, Severe. 
The distribution of severity is summarised in Table 3 and 4 below.  
 
Table 3 Hearing Loss Profile at Screening – Left Ear  
Grade  Frequency  Percentage (%)  Cum. Percentage (%)  
Normal  4  7.41  7.41  
Mild  19  35.19  42.59  
Mild to Moderate  25  46.30  88.89  
Moderate  4  7.41  96.30  
Moderate to Severe  1  1.85  98.15  
Severe  1  1.85  100.00  
Total  54  100.00  
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Table 4 Hearing Loss Profile at Screening – Right Ear  
Grade  Frequency  Percentage (%)  Cum. Percentage (%)  
Normal  2  3.77  3.77  
Mild  20  37.74  41.51  
Mild to Moderate  27  50.94  92.45  
Moderate  4  7.75  100.00  
Moderate to Severe  0  0.00  
  
Severe  0  0.00  
  
Total  53  100.00  
  
  
In the majority of cases the severity of hearing loss at screening ranges between mild and 
moderate. Very few cases are diagnosed as severe.  
  
7.1.4 Tinnitus Profile  
Tinnitus profiles of patients were measured at screening using the following scores: THI, MML, 
TLM and TM. Summary statistics are shown in Table5 below.  
 
Table 5 Tinnitus Scores at Screening - Summary Statistics  
Score  N  Mean  Std. dev.  Min  Max  
THI  54  41.1  22.4  6  94  
MML  54  50.8  17.1  15  85  
TLM  54  42.9  19.7  10  85  
TM  54  6518  3387  250  12500  
 
7.1.5 Analysis  
Scores were obtained at screening V0 and Baseline V2 and every 2 weeks for duration of study. 
Comparisons were made between Baselines V2 and V7 (Week 4/1st week of treatment) and V7 
(Week 14/10th week of treatment) for main effect and between Baseline V2 and V4 (Week 8/4 
weeks of treatment) for interim effect. A placebo/context effect was explored as a comparison 
between screening visit V0 and baseline V2, where participants have not yet received treatment.  
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Short term effects of treatment were measured as a comparison between the last week of 
treatment V7 (Week 14) and V8 (Week 16/2nd week post treatment).   
  
Boxplots and repeated ANOVA were carried out for all sampled measures to determine statistical 
significance.  Paired t-tests were carried out to compare the main effect (change between Baseline 
V2 and V7 (Week 14/10th week of treatment) and interim effect (change between baseline V2 
and V4 (Week 8/4th week of treatment).   
  
The potential placebo/context effect was analysed in an exploratory manner comparing measures 
at V0 and Baseline V2.  This was a 4 week run-in period in which intervention is not 
administered, but some beneficial effect may have been observed due to the subjective nature of 
tinnitus.   Paired t-tests compared Screening visit V0 and Baseline V2 to test for evidence of a 
potential placebo/context effect.   
 
7.1.6 Tinnitus Handicap Inventory (THI)  
Change in THI score over time is shown in Figure 13 below. Overall repeated ANOVA was 
statistically significant (p-value <0.001). Paired t-test comparison between Baseline V2 and V7 
(Week 14/10th week of treatment) was also determined to be significant (p-value <0.001). THI 
score decreased from an average value of 34.3 (95% CI: 27.3 – 41.2, N=46) at Baseline V2 to 
24.9 (95% CI: 19.8 – 30.7, N=46) at V7 (Week 14/10th week of treatment). Interim effect (average 
change in THI from baseline V2 to V4 (Week 8/4th week of treatment), was also significant (p-
value = 0.0052), decreased from 34.42 (95% CI: 27.5-41.3, N = 50) at Baseline V2 to 31.12 (95% 
CI: 24.2 – 38.1, N= 50) at V4 (Week 8/4th week of treatment).   
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Figure 14 Boxplot of THI from Screening (V0/Week 0) to end of Treatment Visit (V7/Week 14)  
 
  
  
Significant placebo/context effect was determined for THI score. Average THI score dropped 
from 41.1 (SD 3.04) to 34.4 (SD 3.2) (N = 54) from V0 screening visit to V2 Baseline visit and 
the change was statistically significant (p-value <0.001).  
 
7.1.7 Minimum Masking Level (MML)  
Change in MML score over time was shown in Figure 14 below. Overall repeated ANOVA was 
statistically significant (p-value <0.001). Paired t-test comparison between Baseline V0 and V7 
(Week 14) was also significant (p-value <0.001). MML score decreased from an average value 
of 47.4 (SD=2.54, 95% CI: 42.3 – 52.6, N=39) at Baseline V2 to 38.8 (SD = 2.7, 95% CI: 33.4 
– 43.34, N=39) at V7 (Week 14/10th week of treatment).  Interim effect, (average change in MML 
from Baseline V2 to V4 (Week 8), was also significant (p-value = 0.0088), it decreased from 
48.15 (SD= 2.69, 95% CI: 42.66 – 53.64, N = 33) at Baseline V0 to 43.79 (SD = 3.13, 95% CI: 
37.4 – 50.16, N= 33) at V4 (Week 8).  
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Figure 15 Boxplot of MML from Screening (V0/Week 0) to end of Treatment Visit (V7/Week 14) 
  
 
  
There was evidence of a placebo/context effect for the MML score, which was significant (p-
value = 0.01). Between screening visit V0 and Baseline V2 the average MML score changed 
from 50.8 (SD 2.3) V0 to 46.7 (SD 2.2) (N = 54) V2.   
 
7.1.8 Tinnitus Loudness Matching (TLM)  
The change of TML score over time is shown in Figure 15 below. The overall repeated ANOVA 
is statistically significant (p-value <0.001). The paired t-test comparison between V2 Baseline 
and V7 (Week 14/10th week of treatment) was also significant (p-value = 0.001). The TLM score 
decreased from an average value of 45.3 (SD=2.5, 95% CI: 40.2 – 50.4, N=39) at Baseline (V2) 
to 38.1 (SD = 2.75, 95% CI: 32.5 – 43.6, N=33) at V7 (Week 14/10th week of treatment).  The 
interim effect, (average change in TLM from Baseline V2 to V4 (Week 8/4th week of treatment), 
was also significant (p-value = 0.045), it decreased from 44.63 (SD= 2.61, 95% CI: 39.31 – 50, 
N = 33) at Baseline V2 to 40.18 (SD = 3.28, 95% CI: 33.5 – 46.85, N= 33) V4 (Week 8/4th week 
of treatment).    
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Figure 16 Boxplot of TML from Screening (V0/Week 0) to end of Treatment Visit (V7/Week 14) 
 
 
There was no evidence of a placebo/context effect for TLM score. Average change between 
screening visit V0 and Baseline V2 was less than 1 point, changing from 42.9 (SD 2.68) to 43.4 
(SD 2.1), and was not significant.  
 
7.1.9 Tinnitus Matching   
Change of TM score over time is shown in Figure 16 below. Overall repeated ANOVA showed 
some trend of decreasing values, but was not significant.  Summary values for each visit are 
presented in Table 6 below. 
 
Table 6 TM Scores – Summary Statistics  
Visit  N  Mean  Std. Dev.  Min  Max  
0  40  7265  3472.5  250  12500  
1  40  7265  3472.5  250  12500  
2  52  6043  3253.5  250  12500  
3  40  6344  3380.1  250  12500  
4  33  5454  3326.9  1000  10000  
5  35  5493  3143.9  250  10000  
6  40  5756  3105.8  250  10000  
7  35  6000  2897.8  1000  10000  
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Figure 17 Boxplot of TM from Screening (V0/Week 0) to End of Treatment Visit (V7/Week 14) 
  
 
  
7.2 Clinical Efficacy  
The patient group demonstrated a statistically significant mean improvement in objective 
measures, exhibiting a reduction of 8.6dB in MML and 7.2dB in TLM after 10 weeks of 1-hour 
daily treatments between Baseline Visit (V2/4th week of treatment) and End of Treatment Visit 
(V7/14th week of treatment).    
  
Similarly, the patient group demonstrated a statistically significant mean improvement in the THI 
self-reduction from 41.1pts to 24.9pts (-16.2pts).  This reduction included a statistically 
significant placebo/context effect that constituted 6.9pts of the overall improvement.    
  
The device also demonstrated significant user tolerability in marketing questionnaires, with 34 
(77.3%) (N=44) respondents saying they ‘would recommend to a friend with tinnitus’ and 38 
respondents (86.3%) (N=44) rating the treatment as either ‘effective’ or ‘highly effective’.    
  
These results provide further positive evidence and tangible efficacy for the multisensory 
approach to the treatment of tinnitus.  The MuteButton device previously demonstrated efficacy 
in studies using subjective measures with similar patients (O’Grady et al., 2012).  In 2011, 20 
patients were recruited to a 4 week study. The primary objective of this study was to assess the 
effect of transcutaneous electrical stimulation of the tongue on the symptoms of tinnitus, assessed 
by mean Tinnitus Handicap Inventory (THI) and Tinnitus Reaction Questionnaire (TRQ). Patient 
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compliance was measured by logging when the computer programme was activated; this was not 
adequate as the patient could have run the programme without engaging with the device. 
Although objective measures were not administered during this study, the subjective results 
reported further verify the clinical benefit and user tolerability of the MuteButton treatment.   
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CHAPTER EIGHT: DISCUSSION, CONCLUSION AND 
FUTURE WORK 
  
Chapter Eight, the final chapter, highlights and examines the main findings of this research, 
discusses them in the broader clinical context and finally, processes recommendations for further 
investigations.   
 
8.1 Discussion   
As a Tinnitus Specialist, my career to date has been rewarding but also very challenging.  I spend 
a great deal of my clinical time providing information about tinnitus recommendations for 
rehabilitation and persuading patients about the possible benefits.  Although sound therapy and 
counselling have been well defined and used routinely for the treatment of tinnitus, for the 
majority this have only given temporary relief.  To date, no therapy has been found to be 
uniformly effective in the long term treatment of tinnitus.  This motivated me to investigate how 
the current standard of care could be improved and help me to deliver better outcomes for my 
patients.   
  
The literature review in Chapter Four identifies two main strategies for treating tinnitus, both of 
which have achieved moderate levels of success.  Auditory and electrical stimulation for tinnitus 
treatment are reported as being most effective.  There is also evidence to suggest that 
psychological factors play an important part in the treatment of tinnitus and Cognitive 
Behavioural Therapy (CBT) is considered an effective strategy for tinnitus management.   
  
Currently, there is no commercially available electrical stimulation treatment for tinnitus.  
However, Transcutaneous Nerve Stimulation (TENS) in general has demonstrated some good 
results. Auditory stimulation in the form of maskers and hearing aids is currently the conventional 
treatment for tinnitus.  It has been proposed that sound enrichment or sound therapy including 
Tinnitus Retraining Therapy (TRT), hearing aids or maskers prevent or even reverse the 
neuropathologies that give rise to tinnitus.  There is mixed evidence as to whether or not hearing 
aids provide relief from tinnitus, in some instances it has been found that hearing aids provide 
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only transient rather than enduring relief. However, for many patients, they do not tend to 
acknowledge their hearing loss until after the onset of these neuropathologies and the symptoms 
of tinnitus; unfortunately at this stage it may be too late to lastingly treat tinnitus simply through 
sound enrichment.    
  
TRT which uses counselling and sound enrichment to help people habituate to their tinnitus has 
been successful, however its main problem is motivating people to persist, as it can take up to 1-
2 years to observe stable effects (Dobie, 1999).  There is also a need for better experimental 
designs in the studies of TRT efficacy (Wilson et al., 1998; Kroner-Hewitt et al., 2000; Henry et 
al, 2005). The Neuromonics Treatment System is a treatment that combines regular use of a 
noise-masker device with structured psychological counselling.  The Minimum Masking levels 
(MML) obtained in our study compare favourably to studies of the Neuromonics Treatment 
System, and although Goddard et al. (2009) confirmed that Neuromonics appears to reduce the 
effects of tinnitus on an individual’s daily life, future studies are needed to look at larger groups 
of subjects and longer follow-up regarding the efficacy of this device. ANM’s T30 Coordinated 
Reset device is a sound therapy aimed exclusively at treating ‘tonal’ tinnitus.  The subjective 
results obtained in our study compare favourably with studies using ANM device (Tass et al., 
(2012); Adamchic et al., 2012).   Electroencephalograph testing (EEG) was used as their objective 
measure, however there is little evidence to support its efficacy and in my opinion additional 
evidence is needed to evaluate the value of including quantitative EEG testing for tinnitus.   
 
Studies have also demonstrated that CBT has helped patients reduce tinnitus related distress 
(Zachriat & Kroner-Hewitt, 2004) and a Cochrane review demonstrated that CBT can have an 
overall effect on the qualitative aspects of tinnitus and also improve how the patients manage the 
condition (Martinez-Devesa et al., 2007).  While we believe that psychological counselling could 
provide additional benefit, we did not include counselling in this study of our treatment. However 
we did measure subjective benefit under the philosophy that verifiable objective improvement 
without tangible subjective relief to the patient is of little treatment value.   
  
The aim of the study described in this thesis was to evaluate the impact of acoustic and tactile 
multi-modal neuromodulation on objective and subjective measures of permanent intractable 
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tinnitus.  The results of the study demonstrated positive evidence and tangible efficacy for the 
multisensory approach in the treatment of tinnitus following 10 weeks of 60 minute daily 
treatments.  Bias was minimised through anonymised participation and use of objective and 
subjective internationally recognised outcome measures.   
  
Table 7 Comparative treatments and results  
 MEASURES  MUTEBUTTON  NEUROMONICS  ANM T30   
Objective Measures        
MML (dB)  -8.6 dB @ 10 weeks  -12dB @ 52 weeks  -  
TML (dB)  -7.2 dB @ 10 weeks  -  -  
TM (Hz)  Decreasing trend (not 
significant)  
-  -  
Subjective Measures  -  -  -  
THI (Pts)  -16.2 pts @ 10 weeks  -  -  
TRQ (Pts)  -  -39 pts @ 52 weeks  -12 pts @16 weeks  
  
  
Despite the positive results we acknowledge there are several limitations in this study that need 
to be addressed.  The most important of these include blinding and post-treatment results.  
Successful blinding is a challenge in multi-modal stimulation as the patient needs to hear and feel 
both the acoustic and tactile stimuli respectively, in other words turning the stimuli down or off 
would not be an appropriate option for such studies.  The participant and Principal Investigator 
(PI) in this study were unable to be blinded as the PI was involved in prescribing and clinically 
supervising the participants whilst using the device in the clinic prior to taking it home.     
  
To ensure credibility of the novel multisensory treatment, a placebo/context effect was applied. 
This is a 4-week period in which intervention is not administered, but some beneficial effect may 
be observed due to the subjective nature of the tinnitus condition.  However many authors still 
highlight the need for placebo controlled studies, to assess the actual “placebo effect” in tinnitus 
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treatments as expectation alone can stimulate a placebo response (Benedetti et al., 2011; 
Mielczarek et al., 2013).  This is difficult to evaluate in electrical stimulation because the patient 
can feel the electrical current and it is difficult to give non-treatment as a placebo (Kuk et al., 
1989).   
 
A better controlled study would be to carry out the acoustic-tactile training with a sham tactile 
stimulus or to present the acoustic and tactile stimuli separately for 15 minutes each and compare 
either of these conditions to the 30 minute multi-modal stimulation.  
  
It is widely acknowledged that there is a lack of objective tools to measures and quantify tinnitus.   
The assessment of tinnitus severity and its impact depends on a number of valid and reliable self-
report instruments which are increasingly used in tinnitus research and management of tinnitus 
patients.   The use of robust outcome measures is of great importance (Andersson et al., 2007: 
92).  As discussed in Chapter Two, the Tinnitus Hearing Inventory (THI) although verified to be 
useful in measuring tinnitus in a number of studies, does have many areas of weakness.  Kamalski 
et al. (2010) report the THI to be valuable in assessing tinnitus severity; however it is limited in 
that it is not designed or validated to measure effectiveness of tinnitus interventions.  
Furthermore, it consists of a range of questions which may not be relevant to a patient’s particular 
experience and may result in an outcome that does not reflect the patient’s distress.   It is possible 
that the use of open-ended questionnaires (Henry et al., 2005) or alternatively the Tinnitus 
Functional Index (TFI) could assist in improving these issues particularly for research purposes 
(Miekle, 2012).  
 
8.2 Conclusion  
One of the greatest difficulties a clinician faces is an understanding of the neurological 
component associated with tinnitus.  However, I am fortunate that my literature and clinical 
research has enabled me to gain a greater understanding of the condition from a neurological 
perspective.   
  
It is believed that brainstem structures, such as cochlear nuclei, play a major role in tinnitus 
generation and that perception occurs at cortical level.  Studies suggest hearing-loss causes a 
 74  
  
 
 
cascade of neuropathic effects in the central hearing system that is driven by maladaptive 
neuroplasticity.  Shore et al. (2005); Herraiz et al. (2007) demonstrated a functional interaction 
between auditory brainstem structures and input from the branches of the trigeminal nerve and 
that stimulation of these nerves can influence tinnitus perception.      
  
There is long-established evidence of auditory-somatosensory integration.  This thesis focused 
on the involvement of the subcortical auditory structure with possibly the greatest level of 
somatosensory integration, the dorsal cochlear nucleus (DCN), which has been implicated in the 
generation of the illusory sounds of tinnitus (Kaltenbach et al., 2005; Sachaete & Kempter 2008).  
It is believed that this is a neural correlate of the ‘central gains’ phenomenon as discussed in 
Chapter Four and Chapter Five.   
  
There is also evidence of cortical-level auditory-somatosensory integration in the medial 
1division of the medial geniculate body (MGB) and intralaminar nucleus and that the associated 
signal is sent to the basal forebrain via the amygdala. This relationship between tinnitus, the 
prefrontal cortex and the limbic system has been emphasised.  As previously discussed, the limbic 
system mediates the emotional and sympathetic nervous system activity which drives 
maladaptive neuroplasticity which maybe also be a contributing factor to tinnitus (Saunders, 
2007; Kaltenbach et al., 2005).    
  
Many areas still need to be addressed in relation to tinnitus, particularly in developing an 
appropriate and specific training for clinical professional, establishing good methodology for 
carrying out assessments, clinical studies and ongoing research and also in developing patient 
education (Vanneste & De Ridder, 2012).   
  
In terms of developing a suitable and effective treatment, tinnitus interventions can be categorised 
as top-down and bottom-up approaches, with top-down seeking to reverse cortical-level 
correlates of tinnitus and bottom-up approaches addresses the underlying cause of tinnitus, such 
as sensory deafferentation or sensori-neural hearing loss using sound amplification.  As 
previously mentioned in Chapter 5, hearing aids are the conventional treatment for tinnitus and 
are generally well-tolerated bottom-up approaches.  However lack of dynamic range compression 
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can be a major problem for some patients who eventually end up rejecting their hearing aids 
completely.  As discussed, the efficacy of tinnitus masking is difficult to assess from current 
literature.  A systematic review of the evidence of tinnitus treatment reported that hearing aids 
and tinnitus masking are of “unknown effectiveness” (Savage et al., 2011).  However, Hobson et 
al (2010) stated that this should not be interpreted as evidence of lack of effectiveness, but that 
these results demonstrate lack of good quality research as well as a lack of tinnitus management 
approaches.  
 
Even with recent medical advances, no therapy has been found to be uniformly effective in the 
treatment of tinnitus.  It may be considered that no single theory, model or hypothesis will ever 
explain the presence of tinnitus in all those affected.  The most probable future scenario is that 
there will be different treatment approaches for different forms of tinnitus Eggermont (2006).  
However, MuteButton seems to offer the potential for additional assistance to tinnitus patients, 
and could easily be incorporated in a multidisciplinary tinnitus management programme. 
MuteButton's multi-modal approach should theoretically reap the benefits of the both the top-
down and bottom-up approaches described above.    
  
The findings, that audiotactile stimulation can modulate the frequency and loudness of auditory 
perception constitutes a compelling and growing case for multisensory approach to treating 
tinnitus.  From a clinical perspective, this non-invasive multi-modal stimulation treatment carries 
very few risks and is very easy to apply.   The technology is compact, portable and easy to operate, 
and should be considered as a treatment tool in clinical practice in conjunction with hearing aids.    
  
As mentioned in Chapter Two, the initial onset of tinnitus is quite often associated with stress, 
leading to negative emotions particularly if the tinnitus persists.  It can lead to a repeating cycle 
of annoyance, mood changes, fear and anxiety, all of which are associated with tinnitus severity 
(Henry et al. 2005).  Although CBT by itself does not influence the subjective loudness of tinnitus 
or improve the associated depression, it may effectively increase an individual’s quality of life 
by increasing their ability to deal with their tinnitus (Martinez-Devesa et al., 2010).  
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8.3 Future Work   
Due to the subjective nature of this disorder and general lack of understanding of the underlying 
pathophysiology, treatment of tinnitus has been limited, controversial and quite often 
unsuccessful.  There are currently no pharmacological agents specifically recommended for the 
purpose of treating tinnitus (Dobie, 1999). Non-pharmacological and surgical approaches have 
been used in certain cases with limited therapeutic effects.    
  
Although neuromodulation has been reported as a promising treatment for tinnitus, much more 
research is required to analyse and determine its potential, determine exactly the method by which 
it works as well as the brains response to such treatment. More research on neruomodulation in 
tinnitus is focusing on TMs, in particular repetitive transcranial magnetic stimulation (rTMs) 
which has recently been reported to improve tinnitus related distress (Kleinjung et al., 2005; 
Vanneste & De Ridder, 2012).  TMs delivers short but high-intensity current pulse through a coil 
which penetrates the scalp and brain with little attenuation.  A number of studies have been 
carried out and results have been promising, however there is still some controversy over the 
duration of treatment and its efficacy and also on the sub-groups of patients who may benefit 
most.  In some studies effects outlasted the stimulation period up to a year (Kleinjung et al., 2005; 
Khedr e al., 2008), whilst others could not demonstrate any after-effects (Moller et al., 2010: 
702-707).  However TMs is more expensive and more difficult to apply in comparison to 
transcutaneous electrical nerve stimulation (TENs) and transcranial direct current stimulation 
(tDCS). tDCS is a non-invasive cortical stimulation technique which can modulate cortical 
activity and has been reported in several studies to influence working memory, decision making 
and emotional responsiveness. Its effect in treating tinnitus depends on the stimulation site and 
intensity, and duration of treatment.  Pilot studies have demonstrated that tDCS applied to the 
temporal lobe and the dorsal lateral prefrontal cortex can supress tinnitus (Vanneste & DeRidder 
2012).  Although different techniques introduced show promising results, other neuromodulation 
techniques such as transcranial alternative current stimulation (tACS) and vagus nerve 
stimulation (Schnupp, 2011; Engineer et al., 2011; Vanneste & De Ridder 2012) might also show 
benefits in the future.  
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The majority of these studies rely on patient’s self-evaluation of their tinnitus.  Auer et al (2007) 
describe brain-imaging studies which show enhanced cortical responses to somatosensory stimuli 
in hearing impaired humans.  Such functional and structural MRI analysis may be provide 
promising objective diagnostic tools for future research, particularly when distinguishing 
between normals and tinnitus suffers, and could be utilised as objective clinical measurements 
before and after treatment.    
  
A logical continuation of this study is to have a double-blind randomised control trial (RCT) 
examining the benefits of using multisensory stimulation or a comparative study with hearing 
aids comparing the efficacy of both treatments for tinnitus. To ensure successful blinding, an 
assessor would be allocated to collect and summarise the data and be blinded to the treatment 
allocation which would be consistent with current quality assessment of Randomised Control 
Trial (RCT) recommendations (Jadad et al., 1996).    
  
Given the positive results of this study, we intend to follow up with further studies to determine 
the benefits of longer treatment periods in addition to measuring retention at three and six-month 
intervals post-treatment and also include a larger tinnitus population with different hearing 
statuses, including normal, mild, moderate and severe hearing loss.   
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APPENDIX 1 – GP LETTER 
 
Date _______________ 
Dear Dr __________________ 
 
RE: Tinnitus Research Study 
Your patient _____________________________ (DOB___ / ___/____) has consented to 
participate in a Tinnitus Research study.  This study is been conducted by a team of researchers 
at NUI-Maynooth in collaboration with the Hermitage Clinic in Lucan. 
 
The duration of the study is 12 weeks. The recruitment period for this study is June to Sept 2012.  
The aim of the study is to investigate whether a novel, experimental sound to touch translation 
device, called MuteButton, can affect the patient’s awareness of tinnitus.  It involves using the 
device every day for a period of 2 hours.  The stimulation involves audio patterns played through 
a set of headphones and tactile patterns consisting of small electrical pulses delivered to the tip 
of the tongue.   The patient will be invited to attend The Hamilton Institute, NUI-Maynooth or 
Hermitage Medical Clinic, Lucan every two weeks.  They will be given relevant contact details 
if they have any questions during the 12 week period.   Should they develop any side effects or 
unusual symptoms they will be advised to contact us direct.   
 
Should you have any questions, please do not hesitate to contact me direct at 0879976995 or via 
email: caroline.hamilton@nuim.ie.  If you require any further information regarding this study, 
or have any concerns about your patient’s condition, please do not hesitate to contact Mr. Brendan 
Conlon MD, Hermitage Medical Clinic, Lucan, Co Dublin. Tel: (01) 6459601 or via email: 
bconlon@ent.ie. 
 
Yours sincerely 
__________________ 
Caroline Hamilton  
Audiologist/Researcher  
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APPENDIX 2 – LETTER OF REFUSAL 
 
Patients name/address 
Date_______________ 
Dear ____________ 
 
I write to you regarding your recent interest in our Tinnitus Research Study. As previously 
discussed, The Hermitage Medical Clinic in collaboration with NUI Maynooth are running a 
tinnitus research study using a device developed by researchers at the University.  Having 
reviewed your data, it would appear that you do not fit the inclusion criteria for this particular 
study.   
 
However, we intend running further tinnitus studies in due course and if interested we would be 
happy to contact you.  While we cannot guarantee your participation in future studies, should you 
wish to be assessed for inclusion, please contact a member of the research team direct @ 087 
9976995 or email caroline.hamilton@nuim.ie. 
 
Sincerely,  
 
___________________ 
Caroline Hamilton 
Audiologist/Researcher 
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APPENDIX 3 – APPOINTMENT LETTER 
 
Patients name/address:      Date______________ 
Appointment Date: 
 
Dear ________________ 
I write to you regarding your recent interest in our Tinnitus Research Study. As previously 
discussed, The Hermitage Medical Clinic in collaboration with NUI Maynooth are running a 
tinnitus research study using a device developed by researchers at the University.  Having 
reviewed your data, it would appear that you fit the participant profile for this study.   A further 
screening appointment would however be required to verify that you meet all the inclusion 
criteria. This appointment will take place at the Hermitage Medical Clinic, Lucan, Co Dublin.  
Please check in at main reception and you will be directed to our Suite.  
 
You will be required to complete 2 questionnaires on arrival.  Hearing and tinnitus matching tests 
will also be carried out.  The study will be discussed with you and you will be asked to sign a 
consent form.  Duration of this appointment will be approximately 30 - 45 minutes.  Please arrive 
approximately 15 minutes prior to your appointment.   
 
Following your screening appointment you will be contacted within 1-2 weeks and advised as to 
whether or not you have been recommended for inclusion in the study which will take place over 
a 12 week period, commencing July 2012.  As part of this study, you will be required to attend a 
review appointment every 2 weeks during this 12 week period. 
 
While we cannot guarantee your participation in the study, should you wish to be assessed for 
inclusion and are available to attend at the above date and time, please contact a member of the 
research team direct @ 087 9976995 or email caroline.hamilton@nuim.ie. 
Sincerely,  
 
___________________ 
Caroline Hamilton, Audiologist/Researcher  
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APPENDIX 4 – TINNITUS HEARING INVENTORY (THI) 
   
  4 0 2 
  Yes No Someti
mes 
1 Because of your tinnitus is it difficult for you to concentrate? 
 
   
2 Does the loudness of your tinnitus make it difficult for you to hear 
people? 
 
   
3 Does your tinnitus make you angry? 
 
   
4 Does your tinnitus make you confused? 
 
   
5 Because of your tinnitus are you desperate? 
 
   
6 Do you complain a great deal about your tinnitus? 
 
   
7 Because of your tinnitus do you have trouble falling asleep at 
night? 
 
   
8 Do you feel as though you cannot escape from your tinnitus? 
 
   
9 Does your tinnitus interfere with your ability to enjoy social 
activities? 
 
 
  
10 Because of your tinnitus do you feel frustrated?  
 
  
11 Because of your tinnitus do you feel you have a terrible disease?  
 
  
12 Does your tinnitus make it difficult for you to enjoy life?  
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13 Does your tinnitus interfere with your job or household 
responsibilities? 
 
 
  
14 Because of your tinnitus do you find that you are often irritable?  
 
  
15 Because of your tinnitus is it difficult for you to read?  
 
  
16 Does your tinnitus make you upset?  
 
  
17 Do you feel that your tinnitus has placed stress on your 
relationships? 
 
 
  
18 Do you find it difficult to focus your attention away from your 
tinnitus and onto other things? 
 
 
  
19 Do you feel that you have no control over your tinnitus?  
 
  
20 Because of your tinnitus do you often feel tired?  
 
  
21 Because of your tinnitus do you feel depressed?  
 
  
22 Does your tinnitus make you feel anxious?  
 
  
23 Do you feel you can no longer cope with your tinnitus?  
 
  
24 Does your tinnitus get worse when you are under stress?  
 
  
25 Does your tinnitus make you feel insecure?  
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APPENDIX 5 – VISUAL ANALOGUE SCALE (VAS) 
 
 
 
Over the last 2 weeks, can you rate the severity of you tinnitus (please circle) 
 
 
  1 2 3 4 5 6 7 8 9   10 
 
        MILD                          SEVERE 
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APPENDIX 6 – PATIENT INFORMATION SHEET 
 
Tinnitus Research Study  
Introduction 
You are being invited to take part in a research study.  Before you decide to take part it is 
important that you understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and feel free to discuss it with others.  Ask 
us if anything is not clear or if you would like more information.  Take time to decide whether 
or not you wish to take part. 
 
What is the purpose of the study? 
The aim of this study is to investigate whether a novel, experimental device “MuteButton” can 
affect the awareness of tinnitus.  Sound that arrives at the ears naturally will be presented in the 
form of touch patterns on the tongue.  By learning to associate the sounds in the ears with the 
sound patterns on the tongue, we aim to demonstrate that the brain will learn to discriminate the 
real sounds from legitimate external sources from the imaginary tinnitus sounds that are created 
inside the brain.   
 
Why have I been invited? 
You have been invited to participate because you experience tinnitus.  Up to 100 Participants will 
be invited to be pre-screened for the study. Based on the inclusion/exclusion criteria, the first 60 
participants who meet the criteria will be recommended for the 12 week study. 
 
Do I have to take part? 
Participation in this study is entirely voluntary.  It is up to you to decide whether to take part or 
not. If you do decide to take part, you are free to leave the study at any time without giving a 
reason. This will not affect your future medical care in any way.  Any participation you had in 
the study previous to your departure from the study will be stricken from the record and destroyed 
if you so wish.  
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Your doctor may withdraw you from the study if he/she feels this is in your best interest or in 
case of stopping the study early. 
 
What will happen to me if I take part? 
You will meet with the Consultant and research team who will discuss the study with you in 
detail and you will be asked to sign a consent form.   
 
If you agree to take part in this study, you will be invited to attend The Hamilton Institute, NUI-
Maynooth to have certain examinations and tests (called “screening tests”) to help determine 
whether you are eligible to participate. The duration of the first visit will be approximately 45 
minutes. The screening tests include a review of your tinnitus medical history; complete 2 
questionnaires (Tinnitus Handicap Inventory and Visual Analogue Scale).You will undergo a 
tinnitus matching test. The purpose of this test is to help identify the frequency and intensity of 
your tinnitus. The test is similar to having your hearing tested.  You will be asked to wear a set a 
headphones connected to an audiometer (used for hearing tests) and you will be asked to identify 
which of the tones of the audiometer match the tone of the ringing in your ear(s). This is a simple 
procedure in which the researcher adjusts the sound until you indicate that it is the same as your 
tinnitus.  
 
It is possible that after these tests are reviewed, you will not be eligible to take part in this study.  
You will be referred back to your GP and advised of further therapies available that may be 
beneficial.   
If you are eligible to participate in the research study you will advised within 1-2 weeks after the 
screening visit. You will be invited to attend the enrolment visit at the Hermitage Medical Clinic, 
Lucan.  The duration of your second visit will be approximately 1 hour 30 minutes. 
 
At the enrolment visit you will receive an information pack, which will include a user manual 
and instruction of usage for MuteButton, the required accessories for maintenance which include 
harness, mouth piece, headphones and charger.  An appointment card, detailing location, date 
and times of each of your follow-up visits as well as a map for Hermitage Medical Clinic, Lucan 
and the Hamilton Institute – NUI Maynooth. 
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The instructions for use will include information on how to charge, maintain, clean and store the 
device. It is important your device is fully charged before you start to use it. Ensure the charger 
is disconnected before use (or it will not switch on).   
At this visit you will be instructed on how to use the device and as to the frequency/duration of 
use.  During this initial training session you will be instructed on how to insert the device into 
the oral cavity and depress against the tongue.  You will be advised to use it for 30 minutes whilst 
under the supervision of Ms. Caroline Hamilton, Audiologist and Mr. Brendan Conlon, MD, Ear 
Nose and Throat Consultant. 
 
Once the enrolment session is complete, you will be given the MuteButton device to take home 
for 12 weeks.  You will be advised during your first visit to use the device for 2 hours a day, 
preferably at the same time and in the same place every day.  (Advise morning or evening time, 
in a quiet room, no other sounds or distractions in the room.  Avoid any distractions or 
interruptions, such as door bells, phones etc.  If possible avoid turning off the device during the 
2 hours). 
 
The MuteButton device (which is about the size/weight of a mobile phone) has a neck harness 
on it so you can hang it around your neck, close to your chest.  It involves stimulation in the form 
of audio/sound patterns played through a set of headphones which are placed over the ears.  It 
will have a volume control to allow you to increase and decrease volume, as well as a pause and 
a play button.   
At the same time tactile patterns consisting of small electrical pulses will be delivered to the tip 
of the tongue.  You will place the mouthpiece end, just behind the front teeth, such that the tongue 
lies against it when your mouth and jaw are in a relaxed state.  Your lips will close around the 
bottom of the mouth piece.  You can also adjust the stimulus level of the mouth piece.   
 
Your participation will terminate if you experience any of the following side-effects - pain, 
swelling, erythema (redness), tongue or oral mucosa (patchy or dark oral mucous) or dramatic 
increase in tinnitus symptoms.  Any participants who experience mild symptoms will be observed 
in the out-patient setting until complete resolution of symptoms.  Once the enrolment session is 
complete, you will be given the device for 12 consecutive weeks   
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Following your enrolment visit, you will be asked to meet with a member of the research team 
every two weeks during the 12 week period, for 30-45 minutes for follow-up visits (6 follow-up 
visits in total).  At each visit you will be asked to complete 2 Questionnaires (Tinnitus Handicap 
Inventory and Visual Analogue Scale) on arrival as well as the tinnitus matching test. At the final 
visit, you will meet with a member of the research team who will provide you with a debriefing 
of the study and will give you an opportunity to ask further questions if required. 
 
You will be requested to return the information pack (given to you on the enrolment visit) and 
the MuteButton device. The debriefing session will complete your involvement in the study and 
your interaction with the research team.  Approximately 3 months after your final appointment, 
the questionnaires will be emailed to you, once completed you will be asked to return them via 
post/email.   
 
What is the device that is being tested? 
The MuteButton is a device that is being used in experimental research trials to evaluate the effect 
of stimulation on the symptoms of tonal tinnitus.  You have been chosen for this study as you 
experience tinnitus and have also been diagnosed with a high frequency sensory-neural hearing 
loss.  When used according to the instructions the perceived loudness of the tinnitus may be 
reduced for several hours following a treatment session.  It involves stimulation in the form of 
audio/sound patterns played through a set of headphones which are placed over the ears.  At the 
same time tactile patterns consisting of small electrical pulses will be delivered to the tip of the 
tongue.  
 
What are the alternatives for treatment? 
There are a number of other treatments/therapies available for your condition that your 
Consultant, Audiologist or GP will discuss with you.  
 
 
What are the possible risks of taking part? 
Patients who previously participated in the initial study to evaluate this device did not experience 
any adverse events. There is no guarantee this device will be of any benefit to you. .  If you feel 
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any pain, discomfort, worsening of tinnitus symptoms or any adverse reactions while using the 
device at any stage, you must stop using the device immediately and contact Mr. Brendan Conlon 
MD, ENT Consultant at the Hermitage Hospital at (01) 6459601 or via email: bconlon@ent.ie or 
a member of the research team at 0879976995 or via email: caroline.hamilton@nuim.ie during 
clinic hours. Outside of clinic hours, contact the Emergency Department at the Hermitage 
Hospital at (01) 6459016. 
 
What are the possible benefits of taking part? 
The potential benefits if participating in this research study is, that the perceived loudness of your 
tinnitus maybe reduced for several hours following a treatment session. A previous study using 
the same treatment device for 4 weeks, resulted in 60% of patients reported their symptoms had 
‘improved’ or ‘greatly improved’.  The knowledge gained from this study may also be of help to 
other patients in the future. 
 
What happens if new information becomes available? 
If any new information becomes available during the course of the study that may affect your 
willingness to participate, you will be informed of this.  If you decide to withdraw, your research 
doctor will advise you on alternative treatment if available or return to your GP or ENT surgeon 
or whoever was treating patient initially.  If you decide to continue in the study you will be asked 
to sign and date an updated consent form.  Your doctor may decide based on the new information 
it may not be in your best interest to continue in the study.  He/she will explain the reasons and 
arrange for your care to continue. 
 
Will my taking part in this study be kept confidential? 
If you agree to take part, your GP will be informed of your participation in the study. Your study 
doctor and staff will collect information about you. A code will replace your name on all the data 
collected about you. All the data collected will be kept strictly confidential within the limitations 
of the law. All information relating to your personal data will be anonymised will have your name 
and address removed so as to preserve confidentiality. Any information that will identify you in 
any way will also be removed.  
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The data collected will be used for the evaluation of the study, and may be used in the future in 
related or other studies. The data may be submitted to the health authority/notified body for 
registration purposes. Members of health authorities, of Research Ethics Committees or other 
persons required by law may review the data provided.  This data may also be used in publications 
about the medical device.  However, your identity will not be revealed in any compilations, study 
reports or publications.  In order to verify the accuracy of collected data, it is necessary for the 
sponsor to directly compare them with your medical records.  Such checks will only be done by 
qualified and authorized personnel. All such persons are required to and will keep the data 
confidential. 
 
Who is organising and funding the research? 
The research is being organised by a research team from the National University of Ireland 
Maynooth in collaboration with the Hermitage Medical Clinic.  The research is funded by Irish 
Research Council for Science Engineering and Technology. 
 
Who has reviewed the study? 
The study has been reviewed and given a positive opinion by the Hermitage Medical and NUI- 
Maynooth Ethics Committee. 
 
Who do I contact if I have a question? 
Please feel free to address any questions to Mr. Brendan Conlon MD, ENT Consultant at the 
Hermitage Hospital at (01) 6459601 or via email: bconlon@ent.ieor a member of the research 
team at 0879976995 or via email: caroline.hamilton@nuim.ie during clinic hours. 
 
Contact for further information: 
If you or your relative(s) have any questions regarding the study or in case of study related 
injuries you may contact Mr. Brendan Conlon MD, ENT Consultant at the Hermitage Hospital 
at (01) 6459601 or via email: bconlon@ent.ie or a member of the research team at 0879976995 
or via email: caroline.hamilton@nuim.ie during clinic hours. Outside of clinic hours, contact the 
Emergency Department at the Hermitage Hospital at (01) 6459016. 
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If during your participation in this study you feel the information and guidelines that you were 
given have been neglected or disregarded in any way, or if you are unhappy about the process 
please contact the Secretary of the National University of Ireland Maynooth Ethics Committee 
at research.ethics@nuim.ie or +353 (0)1 708 6019. Please be assured that you concerns will be 
dealt with in a sensitive manner. 
 
You will receive a copy of the information leaflet and consent form to keep. 
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APPENDIX 7 – CONSENT FORM 
Tinnitus Research Study  
Name of Study Doctor: 
Patient Identification Number for this trial:       
Patient’s full name and date of birth:   
 
I confirm that I have read and understand the information sheet for the above study and have had 
the opportunity to ask questions. 
 
I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. 
 
I understand that sections of any medical notes may be looked at by responsible individuals from 
the sponsor company or from regulatory authorities where it is relevant to my taking part in 
research.  I give permission for these individuals to have access to my records. 
 
I agree that the data collected for the study will be used for the purpose set forth above, and 
processing by the sponsor company in an anonymous form with respect of the confidentiality of 
my data.  This will not waive any rights that I have under local law. 
 
I agree to take part in the above study. To be signed simultaneously, i.e. same date, by all parties: 
Print Name of Patient   
Date (to be entered by Patient)         
Signature 
 
Print Name of person obtaining the consent  
Date (to be entered by the person obtaining the consent) 
Signature      
Title of person obtaining the consent 
Distribution: original for study file, copy to Patient and copy to hospital notes. 
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APPENDIX 8 - APPTOINTMENT SCHEDULE 
 
If for some reason you cannot attend your appointment please contact us at your earliest 
convenience on 0879976995 or email caroline.hamilton@nuim.ie 
 
It may not be possible to reschedule appointment(s) due to the number of subjects attending, 
as appointments are all booked in advance. 
 
APPOINTMENT DATE TIME LOCATION 
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APPENDIX 9 – CONTACT DETAILS FOR TINNITUS RESEARCH STUDY 
 
Who to contact regarding medical concern(s)? 
If you feel any pain, discomfort, worsening of tinnitus symptoms or any adverse reactions while 
using the device at any stage, you must stop using the device immediately and contact (during 
clinic hours); 
 
 Mr. Brendan Conlon MD, ENT Consultant at the Hermitage Hospital at (01) 6459601 
or via email: bconlon@ent.ie or  
 A member of the Research Team at 0879976995 or via email: caroline.hamilton@nuim.ie 
or caroline.hamilton@nuim.ie  
 The Emergency Department at the Hermitage Hospital at (01) 6459016 (Mon-Fri: 8am-
5pm, Sat/Sun and Bank hols: 10am-5pm). 
 Outside of clinic hours, please go to your nearest Accident and Emergency Department, 
contact a member of the Research Team at 0879976995 and leave a message/contact details.  
A member of the team will return your call. 
 
Who to contact regarding general question(s)? 
Please feel free to address any questions (during clinic hours) to; 
 Mr. Brendan Conlon MD, ENT Consultant at the Hermitage Hospital at (01) 6459601 
or via email: bconlon@ent.ie or  
 A member of the Research Ream at 0879976995 or via email: caroline.hamilton@nuim.ie 
 
Who to contact regarding further information? 
If you or your relative(s) have any questions regarding the study or in case of study related 
injuries you may contact (during clinic hours); 
 Mr. Brendan Conlon MD, ENT Consultant at the Hermitage Hospital at (01) 6459601 
or via email: bconlon@ent.ie or  
 A member of the Research Team at 0879976995 or via email: caroline.hamilton@nuim.ie 
or 
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 The Emergency Department at the Hermitage Hospital at (01) 6459016 (Mon-Fri: 8am-
5pm, Sat/Sun and Bank hols: 10am-5pm). 
 Outside of clinic hours, please go to your nearest Accident and Emergency Department, 
contact a member of the Research Team at 0879976995 and leave a message/contact details.  
A member of the research team will return your call. 
 
If during your participation in this study you feel the information and guidelines that you were 
given have been neglected or disregarded in any way, or if you are unhappy about the process 
please contact; 
 The Secretary of the National University of Ireland Maynooth Ethics Committee at 
pgdean@nuim.ie or 01 708 6018. Please be assured that you concerns will be dealt with in a 
sensitive manner. 
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APPENDIX 10 – INFORMATION FOR USE 
 
 
 
 
 
 
MuteButton Model MB2011 
Instructions For Use 
 
 
Please read instructions carefully before using MuteButton 
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Purpose of the MuteButton Device: 
The MuteButton is a device that will be used in experimental research trials to evaluate the effect 
of stimulation on the symptoms of tonal tinnitus. The stimulation involves audio patterns / music 
played through a set of headphones and tactile patterns consisting of small electrical pulses 
delivered to the tip of the tongue. 
When used according to the instructions contained herewith, the perceived loudness of the 
tinnitus may be reduced for several hours following a treatment session. 
This device is only to be used under direct instructions from your physician / trial clinician. 
He/she will guide you on the optimal usage pattern and monitor your symptoms progress 
throughout the trial period. 
Contraindications: 
 This device should not be used if you have a pacemaker, pulse regulator or any other 
electronic implanted medical devices unless directed to by a physician. 
 This device should not be used if you have diagnosed or suspected heart problems 
unless directed to by a physician 
 This device should not be used if you have any lesions, sores or inflammation of the 
tongue, gums or inside of the mouth. 
 This device should not be used during pregnancy unless directed to by a physician. 
 This device should not be used if you suffer from Epilepsy unless directed to by a 
physician. 
 This device should not be used if you are immunocompromised in any way such as 
if undergoing chemotherapy or infected with HIV unless directed to by a physician. 
Precautions: 
 Only use with the supplied headphones, Sony model “MDR-XD200” 
 During use make sure that the electrode contacts do not come into contact with other 
equipment or conductive parts. 
 Do not use in very cold or warm climates (below +5 or above +50 degrees Celsius) or in 
very humid environments (above 90% Relative Humidity) 
 Do not use at altitudes greater than 2000m 
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 Do not use for more than one hour per day unless directed to do so by your physician / 
clinician. 
 Do not connect any other equipment to the headphone socket. 
 Do not use this device while sleeping or napping. 
 Keep away from children. 
 Portable radio equipment such as mobile phones may interfere with the performance of 
the MuteButton device and should be kept at least 30cm away from it when in use. 
 
Description of the MuteButton Device - Controls, Indicators and Connections: 
Power Button (doubles up as Play/Pause button) 
This button is used for powering the device up when it is off, and also for pausing and re-starting 
treatment when it is on. It can also be used to power the device off by holding it down for 2 
seconds. 
Forward Button and Reverse Button 
In certain circumstances your health care professional may include multiple sound tracks on the 
memory card. In this case these buttons allow you to skip forward or backwards to select different 
tracks. If there is only one track on the memory card then pressing these buttons will have no 
effect. 
Charger Socket 
The supplied charger plugs into this socket to charge the battery. 
Charger Lamp 
This lamp indicates the state of battery charging. It will illuminate green when the battery is 
charging, and orange when the battery is fully charged. 
Headphone Socket 
The supplied headphones should be plugged into this socket when in use, and they can be 
unplugged when the device is stored away. 
Mouthpiece interconnecting cable 
During normal use the mouthpiece (see figure 4) should be placed just behind your front teeth 
such that the tongue lies against it when your mouth and jaw are in a relaxed state. This is 
illustrated in figure 1. 
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Volume control dial 
This dial adjusts the volume of sound in the headphones. Rotate the dial away from you to 
increase the volume and vice versa. 
Stimulus control dial 
This dial allows you to increase or decrease the tongue stimulation level. Rotate away from the 
mouthpiece cable to increase the stimulation level and vice versa. 
Micro-SD card Slot 
Your physician / clinician will insert a micro-SD card into this slot on your device. It contains 
information relating to the specific audio and stimulation patterns that is deemed most suitable 
for your particular tinnitus characteristics. The device will not function if this card is removed or 
if an alternative card is inserted. 
Electro-tactile stimulus indicator lamp 
This lamp indicates the state of electro-tactile stimulation. It will illuminate yellow when 
stimulation is active. 
 
Using the MuteButton Device: 
 The MuteButton device is designed to hang from a neck harness close to the chest. The 
supplied headphones are placed over the ears, and the mouthpiece is then to be placed 
just behind the front teeth such that the tip of the tongue makes contact with the electrodes 
and the lips close around the connecting cable.  
 Before the device can be used, the charger must be disconnected or it will not switch on. 
Press the Play button briefly to power the device on. The light in the 12 O’clock position 
will illuminate immediately and two seconds later a clockwise rotating pattern of blue 
lights will coincide with the start of stimulation playback. 
 At this point the audio volume and tongue stimulus level can be adjusted to comfortable 
levels. 
 The stimulus will continue for the duration of the treatment session. A slowly rotating 
light in the anti-clockwise direction indicates the time remaining in the treatment session 
– when that light rotates one full circle back to 12 O’clock the session is complete and 
the device will automatically shut down. 
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 The treatment session can be paused at any stage by pressing the Play button, and resumed 
by pressing the play button again. If the session is paused for more than 10 minutes it 
will automatically shut down. 
 The device can be manually shut down at any stage by holding the Play button down for 
2 seconds. 
 The Forward and Back buttons will only operate if your treatment profile contains 
multiple stimulation tracks and in that case can be used to skip forward or back to select 
different tracks. 
 The device will automatically shut down if the micro-SD card is removed as this is 
essential to the operation of the device. 
 The slowly rotating light will change colour from green to orange when the battery goes 
low. When this happens there is still enough energy in the battery to complete the current 
treatment session but once the session is complete the supplied charger should be 
connected to re-charge the battery.  
 When the charger is connected the device will not operate (it will remain shut down) for 
safety reasons. The charge light adjacent to the charger socket will be green then the 
battery is charging and orange when the battery is fully charged.   
 
Cleaning and Sterilization: 
 The control device should only be cleaned with a dry cloth, or if that is not effective iso-
propyl alcohol can also be used. If the control device does get wet, please contact 
MuteButton for a replacement to minimize the risk of electrical shock. 
 Sterilization should not be required often during normal use, where no other person or 
property comes into contact with it. If you suspect that something else may have come 
into contact with it then the intra-oral device (mouthpiece) can be sterilized by immersing 
the mouthpiece part in Milton Sterilizing Fluid at room temperature (20 degrees Celsius) 
for a minimum of 15 minutes.  
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Maintenance, Storage and Disposal: 
 A weekly visual inspection should be carried out to ensure there is no physical 
damage or for evidence of liquids ingress into the control device and for any 
discolouration or damage of the intra-oral part. 
 When not in use the device should be kept in the supplied case. 
 Ensure that the device is stored in a dry location that is not colder than -5 degrees 
Celsius or warmer than 50 degrees Celsius or has a relative humidity level that is 
more than 90%. 
 The internal battery B1 is a lithium-Polymer type and as such does not contain 
environmentally damaging chemicals.  If should be returned to MuteButton for safe 
disposal at end of it’s useful life and should not be disposed o as domestic waste. 
 
Troubleshooting: 
 Below are a few common problems and suggestions on how they may be circumvented. 
If attempting these does not solve the problem please contact MuteButton. 
Device does not power on: 
 The device will not operate while the charger is connected, please disconnect the charger 
before pressing the power button. 
 Check that the device is charged by connecting the charger and waiting until the charge 
LED is the colour orange.  Make sure that you press the power button for at least a half 
of one second, very short presses may not cause the device to latch on.  
 Make sure that the supplied micro-SD card is fully inserted with the text side facing up. 
The sound level is too low: 
 Try to adjust the audio volume level by rotating the volume control dial anti-clockwise. 
The sound is distorted: 
 Check that the headphone connector is fully inserted and that the headphone connector is 
clean. 
 Try adjusting the audio volume level to be lower by rotating the volume control dial 
clockwise. 
 Ensure you are using the supplied headphones: Sony model “MDR-XD200” 
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The tongue stimulation level is too low: 
 Try to adjust the stimulation level by rotating the stimulation control dial anti-clockwise. 
The lights turn green, then orange briefly when powered up and then shuts down again: 
 This occurs when the charger is connected, please disconnect the charger and try to power 
the device on again. 
The lights turn red briefly when powered up and then shuts down again:   
 This is the indication that the device has not passed its own self-testing and is indicative 
of a hardware failure or a micro-SD card error. This device should be returned to 
MuteButton. 
